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in the Brain. 
ABSTRACT 
A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University. 
Thomas Jeffrey Martin 
Virginia Commonwealth University 
Director: Dr. Billy R. Martin 
Antagonists have been crucial in the characterization of nicotine's phannacology. Initial 
evidence for the existence of central nicotinic receptors was based on the fact that nicotine 
produced a number of behavioral effects that were antagonized by ganglionic blockers that 
crossed the blood-brain barrier, such as mecamylamine and pempidine. Although the 
mechanism of action of these compounds has been studied extensively in the periphery, 
little is known about their mechanisms of action in the brain. These compounds are 
thought to be noncompetitive antagonists due to the fact that they do not compete for 
agonist binding to brain homogenate in vitro. However, pharmacological evidence in 
support of noncompetitive antagonism is lacking. 
Dose-response curves for nicotine were determined in the presence of various doses of 
pempidine for depression of spontaneous activity and antinociception in mice. Pempidine 
was found to shift the dose-response curves for these effects of nicotine in a manner 
consistent with noncompetitive antagonism. A number of mecamylamine analogs were 
investigated for antagonism of these central effects of nicotine as well. These studies 
revealed that the N-, 2-, and 3-methyls were crucial for optimal efficacy and potency and 
suggests that these compounds possess a specific mechanism of action, possibly involving 
a receptor. Furthermore, the structure-activity relationships for the mecamylamine analogs 
xiii 
were found to be different than that previously reported for the agonists, suggesting that 
they do not act at the same site. 
The binding of [3H]-L-nicotine and [3H]-pempidine was studied in vitro to mouse brain 
homogenate and in situ to rat brain slices. The in situ binding of rH]-L-nicotine to rat 
brain slices was quantitated autoradiographically to discrete brain areas in the presence and 
absence of 1, 10 and 100 J.l.M nicotine and pempidine. Pempidine did not effectively 
displace [3H]-L-nicotine binding. The studies with [3H]-pempidine failed to demonstrate 
saturable binding. 
The evaluation of the antagonism of nicotine by mecamylamine and pempidine 
presented in this thesis supports a noncompetitive action of these compounds in the brain. 
The shift in the dose-response curves for nicotine, the structure-activity relationship for 
mecamylamine analogs and the binding studies are consistent with this hypothesis. The 
noncompetitive nature of these compounds suggests that they do not compete for the 
binding site of the agonist, and that endogenous nicotinic antagonists may exist in the 
brain. 
I. General Introduction 
A. Preface 
Interest in the phannacology of nicotine arose due to the prevalence of tobacco use 
following the commercialization and production of finished products from tobacco. 
Following its isolation from tobacco and subsequent synthesis, nicotine was shown to 
produce a myriad of pharmacological effects both centrally and peripherally. 
Investigations of nicotine's phannacology resulted in the characterization of a major 
neuronal system that came to be known as the nicotinic cholinergic system. Nicotine was 
also one of the first compounds that was thought to interact with a specific endogenous 
component of neurons and contributed to the development of receptor theory. Indeed, 
more is known about the molecular morphology of the nicotinic cholinergic receptor than 
any other receptor. The antagonists of nicotine have been crucial for the development of 
nicotine's phannacology and in the classification of peripheral and central nicotinic 
receptors. The effects of nicotine that are attenuated by nicotinic antagonists are attributed 
to nicotinic cholinergic receptors, however evidence is being accumulated that suggests 
that the antagonists may not be acting directly at the receptor. Little is known regarding 
the events that lead to the phannacological effects of nicotine subsequent to receptor 
binding, and even less is known regarding the mechanism of action of the antagonists in 
the CNS. A greater appreciation of the mechanism of action of nicotine in the eNS can be 
obtained by investigation of the antagonists. 
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B. Tobacco Vse and Nicotine 
The fIrst record of tobacco use is a Mayan stone carving dated at 600 to 900 A. D. 
(U.S. Dept. of Health and Human Services, 1988). The use of nicotine through the 
smoking or chewing of leaves from the Nicotania tabacum and N. rustica plants was 
introduced into various European countries by sailors returning from voyages in the New 
World in the mid 1500's. The genus Nicotania was named after the French ambassador 
to Lisbon, Jean Nicot, who is said to have sent the seed of N. tabacum to the queen 
consort and regent of France, Catherine de Medicis (Encyclo. Britannica, 1985). Nicot 
also touted tobacco as a cure-all throughout Europe in the late 1500's ( V.S. Dept. of 
Health and Human Services, 1988). Before its commercial cultivation began in 
Jamestown, Virginia in 1612, tobacco had been introduced into all parts of the known 
world, including Russia and Japan. In 1619, the production of tobacco had become so 
commercially successful that the crop was used not only to barter for goods, but also to 
pay taxes and for the salaries of public officials. Furthermore, the profit margin of 
tobacco production became so great that in 1621 ,  production limitations had to be imposed 
in order to increase the production of food crops in the English colonies (Encyclo. 
Americana, 1987). 
Tobacco use increased greatly in the following years. Following the development of 
the cigarette shortly after the Civil War and of blended tobacco in the 19 10's, the 
processing and production of fmished products from tobacco became a tremendously 
successful industrial enterprise (V.S. Dept. of Health and Human Services, 1988). From 
1930 to 1940, an average of 347 billion pounds of manufactured tobacco and 1 48 billion 
cigarettes were produced per annum by V. S. companies. Despite growing concerns over 
the adverse health effects of tobacco use, per capita consumption of tobacco in the Vnited 
States increased from 9.62 pounds in 1940 to 1 1 .82 pounds in 1960 (U. S. Bureau of the 
Census, 1967). Although per capita consumption of tobacco products in the V. S. was 
down to 6.9 pounds in 1984, the tobacco industry produced 657 billion cigarettes and 4.5 
3 
billion cigars in the United States alone. The value of all tobacco products produced in the 
United States in 1984 was over $17 billion (U. S. Bureau of the Census, 1987). 
Due to the prevalence of tobacco use in the world, research began in the early 1800's to 
identify the constituents of tobacco that contribute to its habitual use. An oily substance 
was isolated from tobacco by Cerioli and Vanquelin in the early 1800's and was named 
"Nicotianine". This substance was further purified and renamed "Nikotin" by Posselt and 
Reiman in 1828. The empirical formula of this substance was elucidated in the 1840's and 
nicotine was flrst synthesized in the 1890's ( U.S. Dept. of Health and Human Services, 
1988). Since then, numerous investigators have sought to determine the role of nicotine in 
tobacco use. 
The evidence in support of nicotine being the principal component of tobacco that 
contributes to its habitual use is a culmination of chemical and biological data on the 
constituents of tobacco smoke, their absorption into the blood and distribution into the 
brain, and their effects on humans and laboratory animals. An extensive review of this 
subject is provided in The Health Consequences of Smokin�; Njcotine Addiction a report 
of the SUT�eon General (U.S. Dept. of Health and Human Services, 1988). Nicotine has 
been found to be the primary alkaloid present in tobacco smoke (Piade and Hoffman, 
1980) and Benowitz et aI. (1987) have shown that nicotine enters the bloodstream 
following tobacco use. Furthermore, peak blood concentrations are similar following the 
use of a variety of tobacco products (Benowitz, 1987). Given free access to tobacco, 
smokers have been shown to rapidly achieve a blood level of nicotine in the morning 
hours that remains steady throughout the day (Benowitz et aI" 1982). Earlier, 
Schmiterlow et al. (1967) had shown that nicotine was readily distributed into the brains 
of mice and cats following Lv. administration. Other researchers have found this to be 
true for mice (StAlhandske, 1970, Maziere, et aI., 1976), rats (Oldendorf, 1974), and 
rabbits (Maziere, et al.,1976). Therefore, based on these studies and others, nicotine has 
been shown to enter the bloodstream and, consequently, the brain following tobacco use. 
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Nicotine possesses pharmacological properties that are consistent with other drugs of 
abuse. Drugs of abuse have been shown to be positive reinforcers in humans and animals 
(Thompson and Unna, 1977; Thompson and Schuster, 1968). Nicotine has been shown 
to be a positive reinforcer in beagles (Risner and Goldberg, 1983), squirrel monkeys 
(Goldberg and Spealman, 1983), rhesus monkeys (Yanagita, 1977), and humans 
(Goldberg and Henningfield, 1983; Henningfield et al., 1983). Nicotine has been shown 
to be an even more effective secondary reinforcer, where drug administration is associated 
with an external cue (Goldberg et aI., 1981; Spealman and Goldberg, 1982). 
Mecamylamine antagonized both the primary (Goldberg and Spealman, 1982) and 
secondary (Goldberg et al., 1981; Spealman and Goldberg, 1982) reinforcing properties 
of nicotine. Furthermore, nicotine administration decreases smoking in human subjects 
whether administered i.v. (Lucchesi et al., 1967; Henningfield et al. , 1983) or p.o. in the 
form of capsules (Jarvik et al., 1970) or gum (Nemeth-Coslett, et al., 1987; Russell, et 
al., 1976). Conversely, mecamylamine increases cigarette smoking (Stolerman et al., 
1973a; Nemeth-Coslett et al., 1986; Pomerleau et al., 1987). Pentolinium, which does 
not cross the blood-brain barrier, has no effect on cigarette smoking, suggesting that 
nicotine acts centrally to reinforce smoking behavior , and that mecamylamine's 
antagonism is centrally mediated (Stolerman et al., 1973a). Cessation of chronic nicotine 
intake has also been shown to produce a characteristic withdrawal syndrome (American 
Psyhciatric Association, 1987). These data suggest that smoking is a means of obtaining 
nicotine in order to experience its reinforcing properties or prevent withdrawal effects. 
C Phannaco!o� of Nicotine 
1. Physiolo�cal Responses and Behavioral Effects 
Investigations of nicotine's pharmacology have sought to answer other questions which 
are not related to tobacco use, but rather to characterize the nicotinic cholinergic system. 
Nicotine produces a myriad of effects when administered to animals which are peripherally 
mediated, centrally mediated, or a composite of both. Nicotine was fIrst demonstrated to 
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act at autonomic ganglia by Langley and Dickinson in 1889. Dale (1905) demonstrated 
that acetylcholine had nicotinic and muscarinic components that could be separated. 
Peripherally, nicotine's effects can be largely explained by its actions on the 
sympathetic and parasympathetic ganglia, where transient stimulation by nicotine is 
followed by a more prolonged blockade. Nicotine has a biphasic effect on the release of 
catecholarnines from the adrenal medulla and on stimulation of skeletal muscle. In the 
latter tissue however, the stimulant effect is largely masked by a more prolonged 
relaxation. Nicotine also stimulates a number of sensory receptors that include 
mechanoreceptors of the skin, tongue, lung, mesentery, and stomach; as well as 
chemoreceptors in the carotid body, thermal receptors of the skin and tongue, and pain 
receptors. Hexamethonium has been found to antagonize these actions. Composites of 
the ganglionic effects lead to tachycardia and hypertension, increased gastrointestinal 
motility and tone in the gut, and increased salivary and bronchial secretions. Nicotine 
causes nausea and vomiting as a result of stimulation of sensory nerves in vagal and spinal 
afferents in combination with stimulation of chemoreceptors in the area postrema of the 
medulla (Taylor, 1985). Nicotine also stimulates respiration due to activation of 
chemoreceptors in the carotid bodies as well as direct stimulation of central respiratory 
centers at higher doses. Stimulation is followed by respiratory depression due to 
desensitization of the central respiratory centers of the brainstem and neuromuscular 
blockade of respiratory muscles (Westphal, 1982). 
In the CNS, nicotine has an intriguing profile of pharmacological effects which has 
been reviewed in detail (Martin, 1986). As in the periphery, both stimulation and 
depression occur. As mentioned above, nicotine can cause nausea and vomiting due to its 
stimulatory actions on the area postrema of the medulla oblongata. Other stimulatory 
effects include tremors, convulsions, and release of antidiuretic hormone from the pituitary 
(Westphal, 1982). Nicotine has been found to cause EEG activation (Longo et aI., 1954; 
Rinaldi and Himwich, 1955) which may be mediated in part by peripheral afferent C fibers 
6 
(Ginzel, 1987; Murphree et aI., 1967). In addition to the effects mentioned above, 
nicotine has been shown to cause antinociception (Phan, et aI., 1973; Sahley and 
Berntson, 1979; Tripathi, et al., 1982) and alterations in behavior and leaming (Larson, et 
al., 1961; Iwamoto, et al., 1987). Nicotine has been shown to depress activity in rodents 
(Morrison, 1969; Martin, et aI., 1983). A review by Hall (1984) describes temperature 
regulation, sleep and arousal, release of coricosteroids, and water intake as effects of 
intracerebrally administered nicotine. Nicotine has also been found to possess 
discriminative stimulus effects in the CNS (Stolerman, et aI., 1987; Morrison and 
Stephenson, 1969; Rosecrans and Chance, 1978), some of which may not be cholinergic 
(Rosecrans and Chance, 1977; Rosecrans, 1987). Ganglionic blockers that penetrate the 
CNS, such as mecamylamine, have been shown to antagonize most, if not all, of 
nicotine's central effects (Martin, 1986; Stolerman et al., 1983). 
2. Effects of Nicotine on Neurotransmitter Release 
Numerous investigators have attempted to attribute the behavioral effects of nicotine to 
its actions on the release of neurotransmitters in the CNS. Extensive reviews on this 
subject are available (Aceto and Martin, 1982; Balfour, 1982; Rowell, 1987; U. S. Dept. 
of Health and Human Services, 1988). Nicotine has been shown to stimulate the release 
of norepinephrine (NE), dopamine (DA), serotonin (5-HT) and acetylcholine (ACh) 
(Rowell, 1987). The specific behavioral effects associated with each of these various 
neurotransmitters remains unclear, however. 
Nicotine stimulates the release of catecholamines in various brain regions by two 
distinct mechanisms; one that is calcium dependent and occurs at lower doses, and one that 
is not calcium dependent and is similar to the release seen by tyramine. The first process 
occurs with adrenergic nerve terminals in the hypothalamus as shown with both slices and 
synaptosomes. Norepinephrine (NE) released in response to nicotine in other brain areas 
appears to be due to displacement from storage vessicles in that it is calcium-independent 
and occurs only at doses greater than 10 JlM (Balfour, 1982). Nicotine indirectly affects 
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NE release in the locus coeruleus, an important NE-containing nucleus. Peripherally 
administered nicotine stimulates the locus coeruleus, whereas microiontophoresis of 
nicotine onto this structure has no effect (Svensson and Engberg, 1980). Mecamylamine 
has been shown to be an effective antagonist of nicotine's actions on NE release in the 
brain (Balfour, 1982). 
The effects of nicotine on brain DA release and turnover has been studied less 
extensively. Nicotine also increases DA release in striatal slices that is abolished by 
pempidine or the omission of calcium (Giorgiueff-Chesselet et al., 1979). Nicotine has 
also been shown to increase DA release in vivo in the striatum (Giorgiueff-Chesselet et 
al., 1976) and in the nucleus accumbens (Misfud et al., 1989). Nicotine has been shown 
to increase DA release in the mesolimbic and meso striatal dopaminergic neurons, and it 
has been postulated that some of the euphoric effects of nicotine may be mediated by these 
systems. Nicotine appears to modulate neuroendocrine effects through both NE and DA 
release, with noradrenergic neurons being involved in the control of the 
hypothalamic-pituitary-adrenal-axis, and dopaminergic neurons inhibiting the release of 
prolactin, LH, FSH, and TSH (Fuxe et al., 1987). 
Nicotine appears to have little effect on the serotonergic system in the CNS. This 
aspect of nicotine's pharmacology has not been studied extensively, however. Nicotine 
has been shown to reduce the turnover of S-RT in the hippocampus and reduces the 
capacity of hippocampal synaptosomes to accumulate L-typtophan. These changes 
ocurred only after chronic administration of nicotine and were produced by cotinine, 
nicotine's major metabolite, as well. Furthermore, these effect�e� n� antagonized by 
_mecamylamine (Aceto and Martin, 1982; Balfour, 1982). 
Nicotine has been shown to affect ACh release as well. Armitage et a1. ( 1968) 
demonstrated that nicotine would increase the release of ACh from the parietal cortex, 
whereas higher doses decreased release. Cortical EEG activation and inhibition followed 
the stimulated and reduced ACh release, respectively. Morrison (1968) postulated that 
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ACh release was involved in the depressant effects of nicotine on bar-pressing for water 
reward in that physostigmine, at doses that had no effect by themselves, poteniated this 
effect of nicotine. Neostigmine, which does not penetrate the CNS, had no effect. 
Armitage et al. (1966) have likewise shown that nicotine would induce an ear-twitching 
response in cats that was associated with central ACh release, in that physostigmine 
potentiated this response as well. 
D. The Njcotinic Cboljner�c Receptor 
Peripheral Njcotinic Receptors 
The concept of a nicotinic receptor evolved over the past century. In 1889, Langley 
and Dickinson demonstrated that nicotine exerted a direct effect on the gangljon. Langley 
also postulated the existence of a "receptive substance" for nicotine and, in 1914 reported 
that curare would block nicotine's actions on skeletal muscle (Langley, 1905; Langley, 
1914). Dale (1914) found that acetylcholine had effects that could be separated into two 
components, one mimicked by muscarine and the other by nicotine. The existence of 
muscarinic receptors at parasympathetic effector sites and of nicotinic receptors at the 
neuromuscular junction, adrenal medulla, and at both the sympathetic and parasympathetic 
ganglia is now fully appreciated. The use of specific antagonists has resulted in the 
classification of ganglionic and neuromuscular nicotinic receptors as distinct subtypes 
based upon the number of carbon atoms in the chain that attaches the two amino groups 
that results in optimum antagonistic activity. Attempts to isolate this receptor from 
peripheral tissues met with little success until the discovery of a-bungarotoxin and toxins 
from other elapid snakes that bind with high affinity to the peripheral nicotinic receptor 
(Aceto and Martin, 1982). A glycosidic protein has been isolated from electric eel and 
fish, as well as from mammalian muscle, that binds nicotine and acetylcholine 
(Conti-Tronconi and Raftery, 1982). The extensive biochemistry that has been done on 
this protein will be reviewed later. 
2. Central Nicotinic Rec<:ptors 
a PharmacoJQdca! Eyjd<:nc<: 
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The existence of central nicotinic receptors was postulated due to the fact that nicotine 
produced behavioral effects that were antagonized by ganglionic blockers. As mentioned 
previously, nicotine produces a myriad of central effects that are antagonized by 
mecamylamine, a ganglionic antagonist that penetrates the CNS. Antagonism of the 
effects of nicotine has also been seen by a number of investigators following central 
administration of hexamethonium. These effects include hypotension (Armitage and Hall, 
1967; Feldberg and Guertzenstein, 1976), hypothermia (Hall, 1972), salivation (Hall and 
Reit, 1966) and motor reflexes (Hall and Reit, 1966). These observations led 
investigators to postulate the existence of a central nicotinic receptor of the C6 type. 
However, other investigators have shown that dihydro-B-erythroidine will antagonize 
nicotine centrally, suggesting the existence of CIO nicotinic receptors in the CNS as well 
(Bradley et al. ,  1699; Bradley and Dray, 1976; Bradley and Lucy, 1979). Aceto et al. 
(1969) demonstrated that nicotine-induced convulsions were blocked by the ganglionic 
blockers cblorisondarnine, pentamethonium, mecamylamine, and hexamethonium, but not 
by atropine, chlorpromazine, morphine, or phenobarbitone. It has been found by a 
number of investigators that the only compounds that block the nicotine cue in drug 
discrimination are those that block nicotine's effects at autonomic ganglia and penetrate the 
CNS (Stolerman et al. , 1987). It is interesting to note that chlorisondarnine, a quaternary 
ganglionic-blocking agent, antagonizes the nicotine cue when given centrally (Garcha et 
al. ,  1985) but not peripherally (Romano et al. ,  1981). Therefore, these antagonists have 
proven invaluable for the characterization of central nicotinic recepors pharmacologically. 
Other pharmacological evidence for the existence of a nicotinic receptor in the CNS 
comes from studies on the stereoselectivity of nicotine. It has been shown that the 
naturally occuring isomer, (-)-nicotine, has a similar pharmacological profile as the 
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unnatural (+ )-nicotine. Studies of the central activity of these compounds by a number of 
investigators has revealed that (-)-nicotine is only I to 25 times more potent than 
(+)-nicotine in most assays for central nicotinic activity (Martin, 1986). It has been 
postulated that this low degree of stereose1ectivity is due to the flexible nature of nicotine 
and that the nin;?gen atoms of ( +)- and (-)-nicotine can be superimposed using molecular 
models (Aceto e� aI., 1984). Attempts to construct conformationally restricted analogs that 
retain pharmacological activity has been unsuccessful thus far (Martin, 1986). 
Using drug discrimination, several investigators have demonstrated structural 
requirements for nicotinic activity. Chance et al. (1978) found that of a number of analogs 
tested, only 3-pyridylmethylpyrrolidine generalized to nicotine. An intact pyrrolidine ring 
appeared to be necessary for activity and increasing the distance between the pyridine and 
pyrrolidine rings decreased potency. Rosecrans et al. (1978) showed that nomicotine and 
cotinine were less potent than nicotine. Furthermore, Garcha et al. (1982) demonstrated 
that cytisine produced nicotine-like responding to a nicotine cue. Sto1erman et al. (1987) 
showed that cytisine and anabasine generalized to the nicotine cue, although they were less 
potent than nicotine. Cytisine given i.c.v. has also been found to induce changes in 
locomotor activity in rats, an effect that was antagonized by mecamylamine (Pert and 
Clarke, 1987). Rosecrans et al. (1978) showed that nicotine-trained animals did not 
generalize to a quaternary analog of nicotine, supposedly due to its inability to enter the 
brain. The nicotine cue has been found to be selective in that neither arecoline (Meltzer 
and Rosecrans, 1981), picrotoxin, nor chlordiazepoxide (Stolerman et al., 1987) 
generalize from nicotine in nicotine-trained animals. Therefore, there appears to be 
structural requirements for nicotine's central effects. 
b Radioli�and Bindin� Studies 
Early attempts to characterize nicotinic receptors in vitro utilized a number of 
radiolabelled cholinergic ligands other than nicotine due to the lack of availability of 
radiolabelled nicotine of high specific activity (Martin, 1986). Eldefrawi et al. (1970) 
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studied 3H-muscarone binding to housefly brain. These investigators were not able to 
elucidate a high affinity binding site and interpretation of the binding regarding its 
relevance to nicotine was difficult due to the mixed nicotinic and muscarinic properties of 
muscarone. Early studies with radiolabelled tubocurarine and decamethonium likewise 
met with little success as binding to rat brain tissue was found to be of low affinity 
(Eldefrawi et al., 1970). High affinity binding sites have been found for 3H-tubocurarine 
in rat hippocampus, suggesting the existence of CIO type receptors in the CNS (Nordberg 
and Larsson, 1980). Two sites with Kd's of 1.5 and14 nM were reported and nicotine 
was found to be 50 times more effective than tubocurarine in competing for the 
high-affinity binding. Schwartz et al. (1982) studied 3H-acetylcholine binding to rat brain 
and was able to elucidate a high affmity site in the presence of diisopropylfluorophosphate 
and atropine. This binding was found to have a Kd of 12 nM and a Bmax of 4.6 pmoles/g 
tissue. Nicotinic agonists were found to compete effectively for this binding, whereas 
decamethonium and mecamylamine were 3 and 5 orders of magnitude less potent than 
(-)-nicotine, respectively. It has been subsequently shown that the autoradiographic 
distribution of 3H-nicotine and 3H-ACh in the presence of atropine to mammalian brain are 
vitually identical (Clarke et al., 1985a). 
The use of a-neurotoxins to label central nicotinic sites met with popularity in the 
1970's and early 1980's due to their high affinity for peripheral nicotinic receptors and the 
belief that peripheral and central nicotinic receptors were similar. It has been shown that 
the affinity of a-neurotoxins for peripheral and central binding sites are similar (Oswald 
and Freeeman, 198 1) .  Nicotinic receptors partially purified from rat brain and 
electroplaque tissue using affinity chromatography with a-neurotoxins display similar 
chromatographic properties as well (Salvaterra and Mahler, 1976). However, 
investigators have found that a-bungarotoxin is without activity at central and autonomic 
synapses (Chou and Lee, 1969; Duggan et al. , 1976; Ko et at, 1976; Brown and 
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Fumagalli, 1 977; Patrick and Stallcup, 1 977; Misgeld et al. ,  1980). Furthermore, 
nicotinic agonists and antagonists do not compete for this binding with high affinity 
(Salvaterra and Mahler, 1976; McQuarrie et al. ,  1976; Schmidt, 1977; Moore and Brady, 
1 977; Morley et aI. ,  1 977; Ben-Barak and Dudai, 1 979; Block and Billiar, 1981 ) .  
Autoradiograms of  3H-nicotine and 3H-a-bungarotoxin binding to brain reveal unique 
distributions of binding sites for these ligands as well (Clarke et al. ,  1985a). It has been 
shown that a-bungarotoxin binding sites can be physically separated from high-affinity 
nicotine binding sites using affinity chromatography with a-bungarotoxin as the affinity 
reagent (Wonnacott, 1986). Nicotine was found to compete for a-bungarotoxin binding 
to the protein retained on the column only at micromolar concentrations (Wonnacott, 
1986). Whiting and Lindstrom (1988) have proposed the existence of a nicotinic receptor 
family based upon the purification and cloning of nicotinic receptors from a variety of 
tissues, including mammalian brain. It has been shown that the peripheral and central 
nicotinic receptors are quite different in several salient structural features (Whiting et al. ,  
1 987). Therefore, the relevance of central a-neurotoxin binding sites to nicotine's 
pharmacology is questionable. 
The availability of radiolabelled nicotine with high specific activity in the late 1 970's 
and 1980's greatly enhanced investigations of central nicotinic binding sites. The binding 
of 3H-nicotine to rat brain has been found to be saturable and dependent upon temperature, 
time, and pH of the incubation medium (Martin and Aceto, 1981). Due to variations in the 
techniques used, there is a discrepancy in the literature for affinity constants for 
3H-nicotine binding to brain, ranging from 0.2 to 590 nM (Martin, 1 986). However, 
binding sites for nicotine with a Kd in the low nM range have been demonstrated in the 
brains of mice (Marks and Collins, 1982), rats (Romano and Goldstein, 1980), monkeys 
(Friedman et al. , 1985), and humans (Shimohama et al., 1 985; Flynn and Mash, 1 986; 
Whitehouse et al., 1 986). 
There is also a lack of consensus regarding the existence of multiple binding sites and 
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the stereo selectivity of 3H-nicotine binding to brain (Martin, 1986). The number of 
distinct nicotinic binding sites in the CNS varies from one (Marks and Collins, 1982) to 
four (Sloan et al. ,  1984). It has been suggested that the low-affinity sites arise from 
proteolytic degradation of the high affinity site (Lippiello and Fernandes, 1986). The ratio 
of the ICso of (+)- to (-)-nicotine in displacing 3H-(±)-nicotine binding to brain tissue 
varies from 3 to 63 (Martin, 1986). A direct comparison of the binding properties of the 
separate enantiomers of 3H-nicotine by the same laboratory revealed that the binding 
characteristics of 3H-( +)- and (-)-nicotine were similar, differing only in their affinity 
constants. The dextrorotatory antipode was found to posses three-fold less affinity for the 
binding site than its levorotatory counterpart (Vincek et al. , 198 1 ). Subsequent binding 
studies of the displacement of 3H-( -)-nicotine by (+)- and (-)-nicotine were consistent with 
this study (Vincek et aI., 1 980; Sershen et al., 1 98 1 ;  Sloan et al. ,  1983; Abood et aI., 
1 983). These findings are consistent with the low stereo selectivity of nicotine's 
pharmacological effects, as mentioned previously.The existence of noncholinergic 
nicotinic binding sites in brain has been supported by the work of Abood et al.(1 980). 
They have been able to elucidate saturable nicotine binding with high affinity that is not 
displaced by cholinergic ligands. Other investigators have postulated noncholinergic 
effects of nicotine in the brain, supporting the notion of nicotine binding sites that may be 
noncholinergic. Regardless of the cholinergic or noncholinergic nature of the nicotine 
binding sites that have been elucidated to date, it has been shown that none of the nicotinic 
antagonists compete for in vitro 3H-nicotine binding to brain (Martin, 1 986). Romano 
and Goldstein ( 1 980) have suggested that the long incubation used causes an 
agonist-induced shift of the conformation of the receptor to an antagonist-insensitive form. 
Marks and Collins (1 982) have postulated that the agonists and antagonists bind to distinct 
receptors. Binding studies with radiolabelled antagonists that address these issues have 
not been documented to date. 
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3. Biochemical Characterization of the Nicotinic Rece,ptor 
The molecular structure of the nicotinic acetylcholine receptor-ionophore complex 
(nAChR) from electric eel and fish organs has been studied extensively. An excellent 
review of the literature has been provided by Conti-Tronconi and Raftery ( 1982). The 
nAChR has been purified from extracts of the electric organs of a number of species of 
fish and eel as well as from marnma1ian muscle using affinity chromatography with either 
cholinergic ligands (Schmidt and Raftery, 1972; Olsen et al. ,  1 972) or a-neurotoxins 
(Raftery, 1973; Karlsson et al., 1972). This molecule represents the first neurotransmitter 
receptor to be isolated, purified, and reconstituted into membranes with retention of its 
physiological properties. This macromolecule is a glycosidic protein consisting of four 
distinct subunits, termed a, B, y, and li, with a final stoichiometry of a2Byli. The 
biochemical characterization of these subunits is beyond the scope of this discussion, but it 
suffices to note that there is considerable homology between the subunits from different 
fish and eel, as well as mammalian muscle. These five subunits form a rosette-like 
macromolecule with a central pore that is 15 to 25 A in diameter. Each of the subunits 
traverse the membrane several times. Upon depolarization of the membrane, either by 
receptor agonists or electrical stimulation, the pore opens and the ionophore allows cations 
to pass through the pore. Anions do not flow through the pore due to a large number of 
negatively charged moieties at the pore entrance (Conti-Tronconi and Raftery, 1982). 
Using monoclonal antibodies generated from electroplax, Conti-Tronconi et aI. ( 1985) 
isolated a nicotinic receptor from the chick optic lobe and muscle. The central receptor 
was found to possess some homology to the muscle receptor, but displayed significant 
differences in subunit molecular weights as well. Barnard et aI. ( 1 980) found that 
nicotinic receptors isolated from the chick optic tectum in this manner possessed only two 
distinct subunits, whereas the muscle and electroplacque receptors are found to possess 
five. 
Whiting et aI. (1987) have used immune-affinity techniques to purify and clone putative 
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nicotinic receptors from chick and rat brain. These proteins bind nicotine and 
acetylacholine with high affmity, but not a-bungarotoxin. They have found that only two 
distinct subunits exist for this protein and the a subunit is nearly identical for the brain and 
muscle receptors. Conversely, the 13 subunit of the central receptor appears to be quite 
unique and they have concluded that the central receptor is a distant relative of the 
electroplacque and muscle nicotinic receptors. They have also provided evidence that the 
stoichiometric ratio of the subunits in the brain nicotinic receptor is a3132. The 
autoradiographic pattern of localization in rat brain of the monoclonal antibodies that these 
investigators used to purify and clone this receptor is nearly identical to that of nicotine and 
acetylcholine (Swanson et a1., 1987). Therefore, it is apparent that the neuromuscular and 
central nicotinic receptors are quite different, but their relationship to the ganglionic 
receptor is unknown. 
4 Functional Si�njficance of Central Nicotinic Bindin� Sites 
Evidence that the binding sites elucidated in brain for nicotine have pharmacological and 
physiological relevance consists primarily of studies comparing the selectivity, 
structure-activity relationships, and localization of these binding sites in the brain to 
nicotine's central pharmacological effects. The selectivity and structure-activity 
relationships for the discriminative effects of nicotine has been discussed earlier. The 
ability of nicotine, cytisine, and anabasine to generalize to the nicotine cue in rats is well 
correlated with their ability to displace 3H-nicotine binding to brain tissue (Marks and 
Collins, 1982; Romano and Goldstein, 1 980; Scimeca and Martin, 1988). As mentioned 
above, the stereoselectivity of nicotine in displacing 3H-(-)-nicotine binding to brain is 
consistent with its low degree of stereoselectivity in producing central pharmacological 
effects. Muscarinic compounds have not been found to compete effectively for 
3H-nicotine binding to brain tissue, demonstrating that nicotine binding to brain is 
selective for nicotinic compounds (Marks and Collins, 1 982; Romano and Goldstein, 
16 
1980; Scimeca and Martin, 1988). 
The central distribution of 3H-nicotine binding sites in brain has been studied 
extensively using quantitative receptor autoradiography. These studies have revealed that 
3H-nicotine binds to brain slices with a discrete pattern of localization. The greatest 
number of nicotinic receptors have been found in the thalamus, interpeduncular nucleus, 
cortex, superficial layer of the superior colliculus, and medial habenula, whereas the 
hippocampus, hypothalamus, and reticular formation possess relatively few nicotinic 
receptors (Clarke et al., 1985a; Segal et al. ,  1 978; Duggan et al. ,  1 976). This pattern has 
been found to be strikingly similar to the autoradiographic localization of nicotine's 
metabolic effects in brain through 2-deoxyglucose utilization studies (London et al. ,  
1 985). These investigators have found that mecamylamine would completely antagonize 
nicotine's effects on the metabolic activity of central neurons. Therefore, the binding sites 
for nicotine are not uniformly distributed in brain and nicotine's ability to increase the 
metabolism of neurons in a particular brain area is well correlated with the presence of 
nicotine binding sites. This suggests that these binding sites are relevant to the 
pharmacological effects of nicotine. 
E. Nicotinic Antagonists 
1. History 
Nicotinic antagonists have served to define and delineate the various nicotinic 
cholinergic systems in mammals. Their role can be readily appreciated by the previous 
discussion of nicotine's pharmacology and of nicotinic binding sites found in a variety of 
mammalian tissues, as well as electric organs of fish and eel. The remainder of the 
discussion will focus on the antagonists themselves with respect to their mechanism of 
action on the various effects of nicotine and their relevance to nicotinic binding sites. In 
1 956, Stone et al. reported that a tertiary amine, 3-methylaminoisocamphane, termed 
mecamylamine, was found to possess potent ganglion-blocking activity. Prior to this, 
most potent ganglion-blocking agents were quaternary amines of quick onset and short 
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duration of action. Most tertiary amines that had demonstrated ganglion-blocking 
properties at that time either possessed other pharmacological properties or had low 
potency (Stone et al . •  1956). However. these investigators found that mecamylamine was 
potent and had a longer duration of action that was slower in onset than the classical 
quaternary amino compounds. They concluded that such a compound had therapeutic 
potential as an antihypertensive. Spinks and Young fIrst described the ganglion-blocking 
properties of a series of polyalkylpiperidines in 1 958  and found that 
1 .2.2.6.6-pentarnethylpiperidine had the greatest potency of all tested and termed the 
compound pempidine. They demonstrated that pempidine was approximately twice as 
potent as mecamylamine and yet had an LDso four- to seven-fold greater than 
mecamylamine. depending upon the route of administration. These investigators 
concluded that these compounds had therapeutic potential as antihypertensives. however 
the adrenergic antagonists have largely replaced them for this purpose due to their greater 
efficacy and therapeutic index (Taylor. 1987). 
2 Anta�nism of Nicotine 
a Neuromuscular Junction and Electro,plax Tissue 
The mechanism of action of nicotinic antagonists at the neuromuscular junction and 
electroplax tissue has been studied extensively using a variety of depolarizing blockers and 
neurotoxins. This discussion will focus on the studies that have attempted to discern the 
relationship between such compounds and the central nicotinic antagonists. such as 
mecamylamine and pempidine. Mecamylamine was shown to antagonize contractions of 
the frog rectus abdominus muscle induced by octarnethylenebis(carbamylcholine) (B�) 
by van Rossum and Ariens ( 1959) in a noncompetitive manner. They found that 
mecamylamine and chlorisondarnine shifted the dose-response curves of B� downward. 
unlike a number of bis(quaternaryamino) derivatives that shifted dose-response curves to 
the right in a parallel manner. consistent with competitive antagonism. Blackman and Ray 
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( 1964) demonstrated that blockade of muscle twitch i n  the rat phrenic nerve-diaphragm 
preparation by mecamylamine and pempidine was extracellularly mediated in that 
quaternary derivatives of each compound had nearly identical potencies. Using 
microelectrode recordings of the potential of cell body membranes of cockroach 
motoneurones, David and Sattelle ( 1984) demonstrated that mecamylamine blocked 
ACh-induced depolarization in a voltage-independent manner. This suggests that 
mecamylamine is acting on a closed-channel state of the receptor-ionophore complex, in 
that increasing the applied voltage (i.e., less negative) increases the number of open 
channels. In contrast, blockade by d-tubocurarine decreased with increasing membrane 
potential, suggesting open-channel blockade. Pretreatment with a-cobrotoxin 
(a-COTX), a reversible neurotoxin, was found to prevent irreversible blockade of the 
motoneurones by a-BTX, whereas mecamylamine pretreatment had no effect on the 
reversibility of this blockade, suggesting that its site of action is distinct from that of 
a-BTX. 
The histrionicotoxins have proven to be useful compounds for the characterization of 
the channel of the nAChR found in muscle and electroplax tissue. Histrionicotoxin is an 
alkaloid isolated from the skin of Dendrobates histrionicus , a frog native to Colombia. 
This compound, as well as its saturated derivative perhydrohistrionicotoxin (H12-HTX) 
has been shown to produce voltage- and time-dependent blockade of neuromuscular 
transmission through the nicotinic receptor at the motor end-plate (Albuquerque and 
Oliveira, 1 979; Masukawa and Albuquerque, 1 978) .  Aronstam et a1. ( 1 9 8 1 )  
demonstrated that 3H- HlrHTX binding to electroplax tissue was affected b y  the 
conformational state of the receptor ionophore complex. They found that cholinergic 
agonists increased the initial rate and affinjty of 3H-HI2-HTX binding but had no effect on 
the Bmax. It has been shown that cholinergic agonists increase the potency of HlrHTX 
in blocking end-plate currents in frog and mammalian muscle (Lapa et al. , 1 975). This 
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suggests that HI2-HTX binds to a site within the open channel of the nAChR to block ion 
flow. However, the binding kinetics of 3H-H12-HTX suggests that there are multiple 
binding sites. Further evidence for the existence of multiple binding sites for this 
compound is the difference in the ability of carbamylcholine to stimulate the displacement 
of 3H-H1rHTX binding by other compounds. Compounds that interact directly with 
ionic channels, such as phencyclidine, compete more effectively for 3H-HI2-HTX binding 
in the presence of carbamylcholine, suggesting that 3H- H 1 rHTX binds to an 
open-channel form of the receptor. Conversely, carbamylcholine has no effect on 
compounds that do not bind to sites within the channel, such as tetraethylammonium, 
suggesting that 3H-HI2-HTX binds to sites outside of the channel as well (Aronstam et 
al. , 198 1 ) .  
The relationship of  mecamylamine to  perhistrionicotoxin antagonism a t  the 
neuromuscular junction and binding to electroplax has also been investigated. Varanda et 
al. ( 1985) studied the effect of mecamylamine on 3H-H12-HTX binding to electroplax 
nAChR. They found that mecamylamine competed effectively for 3H-HI2-HTX binding 
to electroplax tissue, but that this interaction was not enhanced by carbamylcholine. This 
suggests that mecamylamine may be binding to one of the sites for 3H-H12-HTX outside 
of the ionic channel. Mecamylamine was not found to compete effectively for 3H-ACh 
binding to this tissue. These investigators also studied the ability of mecamylamine to 
block end-plate currents of frog sartorius muscle. They found that mecamylamine 
produced a concentration- and voltage-dependent shortening of mean channel open time 
and the end-plate current (EPC) peak amplitude. A linear relationship between the 
reciprocal of the decay time constant of the EPC and the concentration of mecamylamine 
was demonstrated, suggesting open-channel blockade. Single-channel recordings from rat 
myoballs demonstrated that mecamylamine did not alter channel conductance or reversal 
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potential, but decreased mean channel-open time in a concentration-dependent manner. 
Therefore, these studies collectively indicate that mecamylamine noncompetitively inhibits 
neuromuscular transmission by binding to an open-channel form of the receptor to 
decrease open-channel time and that this binding site is not located within the channel 
itself. 
b Gan�lia 
The ganglionic-blocking properties of mecamylamine was ftrst described by Stone et al. 
( 1956). These investigators found that mecamylamine was a speciftc antagonist for 
nicotinic stimulation of the ganglia. They found that vascular responses in the dog 
attributed to autonomic ganglia, such as carotid occlusion and peripheral vagal stimulation, 
were antagonized in a dose-dependent manner by mecamylamine. Both 
acetylcholine-induced hypotension and epinephrine-induced hypertension were potentiated 
by mecamylamine, suggesting blockade of compensatory mechanisms through the 
ganglia. They further demonstrated mecamylamine's ganglion-blocking effects in the 
nictitating membrane of the cat superior cervical ganglion, where mecamylamine blocked 
contractions induced by preganglionic electrical stimulation, but not by direct 
administration of epinephrine. Mecamylamine was also shown to produce decreases in 
mean arterial pressure and heart rate in anesthetized dogs and cats that were qualitatively 
similar to quaternary ganglionic-blockers, although slower in onset and longer in duration. 
These investigators found that mecamylamine had no atropine- , curarc-, or 
antihistaminic-like activity. 
Other ganglion-blocking effects have been documented for this compound, as well as 
pempidine. Bentley and Sabine ( 1 963) found that mecamylamine blocked 
electrically-stimulated contractions of the guinea-pig vas deferens at the ganglion and 
found no evidence of a bretylium-like action. This finding was corroborated by Clarke 
and Capps (1972) in the rabbit ileum. Likewise, mecamylamine and pempidine were 
found to decrease gastrointestinal motility in dogs, rabbits, and guinea pigs (Garg, 1966). 
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Gokhale et  al. ( 1967) found that mecamylamine and pempidine potentiated the actions of 
acetylcholine and epinephrine on the iolated rat ileum but totally blocked the actions of 
nicotine. Therefore, these investigations have provided considerable evidence that 
mecamylamine and pempidine act directly at autonomic ganglia 
Due to the availability of a variety of isolated tissue preparations, the mechanism of 
action of these compounds has been studied more intensely at autonomic ganglia than at 
any other site. A scheme for the classification of ganglionic blockers was proposed by 
van Rossum et al. ( 1962) following the analysis of the mechanism of a number of 
ganglionic-blockers. By analyzing the patterns of the shift of dose-response curves for 
nicotinic agonists by these compounds, three distinct categories were found to exist. The 
depolarizing blockers are termed class I compounds, and the nondepolarizing blockers are 
termed class II and III. Class II compounds are the competitive blocking agents, such as 
hexamethonium, and class III compounds are the noncompetitive blocking agents, such as 
chlorisondamine. The nicotine dose-response curves for contractions of guines pig 
jejunum were shifted downward and to the right by mecamylamine and pempidine. These 
compounds were therefore termed class II-III due to the fact that they exhibited the 
characteristics of both types of antagonism, with pempidine showing a greater degree of 
competitive antagonism than mecamylamine. 
Lees and Nishi (1972) investigated the mechanism of action of mecamylamine on the 
rabbit superior cervical ganglion using intracellular recording techniques. They found that 
mecamylamine, but not hexamethonium or d-tubocurarine, inhibited post-tetanic 
potentiation. Post-tetanic potentiation arises predominately as a result of presynaptic 
facilitation of neurotransmitter release, and therefore suggests that mecamylamine 
possesses presynaptic actions. By measuring the excitatory postsynaptic potentials of the 
neurones in response to a train of stimuli, they found that the fractional release of readily 
available ACh was actually increased by mecamylamine, but the amount of ACh readily 
available for release was decreased. The net effect of these opposing actions was an 
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overall decrease in the release of ACh by a presynaptic stimulus, and the time course of 
this effect followed that of inhibition of post-tetanic potentiation. Interestingly, 
mecmaylamine has been shown to have no effect on post-tetanic potentiation of the 
neuromuscular junction (Bennett et al. ,  1957). Lees and Nishi (1972) also demonstrated 
that mecamylamine's only effect on the postganglionic fiber was to decrease the excitatory 
postsynaptic potentials in response to ACh as it had no effect on membraine excitability or 
resting membrane potential. This was found to be true for hexamethonium and 
d-tubocurarine as well. Their conclusions were therefore that mecamylamine had both 
presynaptic and postsynaptic effects at autonomic ganglia. 
Ascher et al. ( 1979) studied mecamylamine's antagonism of the parasympathetic 
neurones at the rat submandibular ganglion by a two microelectrode voltage-clamp 
technique. They found that tubocurarine and hexamethonium produced greater blockade 
of agonist-induced currents in the presence of increasing concentrations of agonists. This 
blockade was voltage-dependent as well, and the data supported a sequential scheme 
whereby these agents bind to the receptor only in an open-channel form. Conversely, 
mecamylamine and trimetaphan were found to produce a blockade that was 
voltage-independent and decreased with increasing agonist concentration, suggesting that 
mecamylamine acts with the closed-channel form of the receptor. 
These studies suggest that mecamylamine antagonism at autonomic ganglia occurs by at 
least two mechanisms. Presynaptically, mecamylamine decreases the amount of 
acetylcholine release in response to a depolarizing stimulus. Postsynaptically, 
mecamylamine alters the response of the nuerone to acetylcholine. It appears to do this in 
a competitive manner, but is clearly different from hexamethonium in its actions in that 
mecamylamine favors a closed-channel form of the receptor. 
c, Central Nervous System 
The mechanism of action of nicotinic antagonists in the brain has not been characterized 
to the same extent as in the periphery largely due to the lack of available models and tissue 
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preparations for measuring nicotine's central effects. As mentioned previously, nicotine 
produces a myriad of central behavioral and biochemical effects that are antagonized by 
mecamylamine and pempidine, but neither of these compounds displace in vitro 
acetylcholine or nicotine binding to brain tissue. Evidence that mecamylamine is acting 
centrally include administration into the brain directly to antagonize nicotine's effects (WU 
and Martin, 1983; Hall, 1972; Armitage et al., 1966). Hall ( 1972) also demonstrated that 
hexamethonium would mimic mecamylamine in antagonizing nicotine-induced 
hypothermia, salivation, and motor reflexes only when administered centrally, as this 
quaternary compound does not cross the blood-brain barrier. Furthermore, Stolerman et 
al. ( 1987) using drug discrimination have reported that peripheral nicotinic antagonists that 
do not cross the blood-brain barrier do not block the nicotine cue, whereas mecamylamine 
is a quite effective antagonist. Mecamylamine has also been shown to antagonize the 
hyperpolarization of cultured astrocytes from rat brainstem and spinal cord induced by 
nicotine and acetylcholine (Rosli et al., 1988). 
Stolerman et al. ( 1 987) studied mecamylamine's ability to block nicotine's 
discriminative stimulus effects in an attempt to determine whether mecamylamine acted 
competitively or noncompetitively. The pattern of shift for percent correct lever 
responding is similar to the fmdings of van Rossum et al. ( 1962) in the guinea pig jejunum 
in that the dose-response curves for nicotine were shifted downward and to the right. 
However, the pattern of shift for depression of response rate was markedly different in 
that the curves were shifted to the right in a parallel manner, suggesting competitive 
antagonism. Several aspects of this study make interpretation of the data difficult. 
Specific EDso values with corresponding confidence intervals for nicotine at each dose of 
mecamylamine were not reported for either effect. There appears to be a lowering of the 
maximum effect of nicotine in producing correct lever responding by mecamylamine, but 
the statistical significance apparently was not determined. As mentioned previously, 
mecamylamine's antagonism of nicotine-induced depression of response rates was 
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overcome by increasing the dose of nicotine. This was a confounding factor in that the 
maximum dose of nicotine that could be tested to overcome the antagonism of correct lever 
responding by mecamylamine was limited by the suppression of response rate, and 
evaluation of the data at the higher doses of nicotine is difficult to interpret 
3. Structure-activity Relationships 
The inability of mecamylamine and pempidine to displace the binding of 3H-nicotine 
from brain tissue suggests that they act at a different site than the agonist. However, 
binding studies have not been conducted with the antagonists themselves. If these 
compounds act at receptors, they should possess structural requirements for activity. 
Furthermore, a comparison of the structure-activity relationships of the agonists and 
antagonists should provide insights as to the likelihood that they are acting at the same site. 
Mecamylamine (N,2,3,3-tetramethyl-2-norbornamine) possesses three chiral centers, 
making eight stereoisomers theoretically possible (Figure 1) .  However, two of the chiral 
centers (carbons 1 and 4) are connected by a methylene bridge, limiting the possibilities to 
four. The isomers are divided into two groups, namely the exo- and endo-isomers. When 
MECAMYLAMINE PEMPIDINE 
Figure 1 .  Structures of mecamylamine and pempidine. 
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the nitrogen extends away from the carbon cage, the compound is referred to as 
(±)-exo-mecamylamine. When the nitrogen is beneath the carbon cage, the comJX>und is 
termed (±)-endo-mecamylamine. The structure-activity relationships of mecamylamine 
analogues in antagonizing nicotine-induced convulsions and pupil dilitation in mice was 
studied by Stone et al. (1962). Optical isomerism was found to have a minor role in the 
activity of these compounds, and mecamylamine was found to be the most JX>tent of all 
compounds tested. The methyl groups at the N, 2 and 3 JX>sitions were found to be 
necessary for activity. The structural requirements for antagonism of nicotine-induced 
convulsions were correlated with ganglionic blockade (r= 0.95), suggesting a similar 
mechanism may be involved. These findings led Stone et al. ( 1962) to conclude that 
mecamylamine has a specific mechanism, JX>ssibly involving a receptor. Unfortunately, 
confidence intervals for the estimated EDso's of each compound were not given and it is 
not apparent which changes produce a statistically significant alteration in the activity of 
mecamylamine. Furthermore, convulsions induced by nicotine occur at relatively high 
doses compared to other central effects and may therefore be a less sensitive assay for 
antinicotinic activity. 
Bretherick et al. ( 1959) examined a number of pempidine derivatives in the cat 
nictitating membrane. It was found that the nature of the N-substitution was important for 
activity. The N-ethyl homologue of pempidine was found to be slightly more potent that 
the parent compound. Substitutions that decreased the base strength of the nitrogen 
resulted in greatly diminished activity, whereas electron-<ionating groups in this position 
enhanced the activity somewhat. Three of the four methyls in the 2- and 6-positions were 
required for activity, however substitutions in the 4-position had no significant effect. The 
pyrollidine counterpart of pempidine (N,2,2,5,5-pentamethyl pyrollidine) was found to be 
less potent than pempidine, and all four methyls in the 2- and 5-positions were necessary 
for activity. Double bonds in the 2:3 or 3:4 positions of pempidine, as well as in the 3:4 
JX>sition of its pyrollidine counterpart did not significantly alter activity. A noncyclic 
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analogue, di-t-butylamine was found to be approximately equipotent with pempidine. 
These findings suggest that the base strength of the nitrogen and the substituents of the 
adjacent carbons are important for the pharmacological activity of pempidine at the 
ganglion. 
F Objectiyes 
The objective of the research presented in this thesis is to more clearly define the 
antagonism of nicotine's effects in the brain by the reversible ganglionic blockers 
mecamylamine and pempidine. More specifically, the competitive and noncompetitive 
nature of this antagonism is explored. If the antagonists act at the same site as nicotine, 
they may be a valuable tool for the determination of the conformational states of the 
nicotinic receptor necessary for neuronal activation. If these compounds are found to be 
noncompetitive however, they may be useful tools for understanding the biochemical and 
metabolic events that lead to the pharmacological effects of nicotine subsequent to receptor 
binding. Therefore, in order to obtain a better understanding of nicotine's central 
pharmacology, it is necessary to characterize the interaction of nicotine and central 
nicotinic antagonists with the nicotinic receptor. 
To determine if the antagonists act at the same site as the agonists, behavioral assays 
and radioligand binding techniques were utilized. The competitive or noncompetitive 
nature of the antagonism of nicotine by pempidine was assessed using in vivo assays for 
nicotine's central effects. The structure-activity relationship for mecamylamine's 
antagonism of nicotine's effects was determined in order to address the possibility that the 
antagonist interacts with a receptor and to determine whether these compounds act at the 
same site. The binding of rHJ-L-nicotine and rHJ-pempidine was characterized in vitro 
and in situ to brain tissue. Quantitative autoradiography was also utilized to determine the 
interaction between these compounds. By studying this interaction in vivo and in vitro 
one may be able to better delineate between competitive and noncompetitive anagonism of 
nicotine by these compounds. 
II. Phannacological Characterization of the Interaction in vivo Between 
Nicotinic Agonists and Antagonists 
Introduction 
Central nicotinic antagonists have yet to be fully characterized regarding the competitive 
or noncompetitive nature of their antagonism of nicotine using in vivo assays for nicotine's 
behavioral effects. The study by Stolerman et aI. ( 1987) on mecamylamine's antagonism 
of the nicotine cue in rats is difficult to interpret for the reasons mentioned previously. The 
characterization of the antagonism of other behavioral effects of nicotine by central nicotinic 
antagonists may provide insights into this interaction in vivo and determine the relevance of 
the observation that these compounds do not compete in vitro for agonist binding sites. 
Nicotine produces a myriad of other central effects, including depression of spontaneous 
activity and antinociception, that are antagonized by central nicotinic antagonists. 
However, the competitive or noncompetitive nature of these central nicotinic antagonists for 
these central effects of nicotine has yet to be documented. 
Nicotine has been shown to produce depression of spontaneous activity in a number of 
species. Morrison and Armitage (1967) demonstrated that nicotine produced depression of 
spontaneous activity in mice in a dose-dependent manner. Marks et al. ( 1986) 
demonstrated a similar effect in four different mouse strains. Morrison and Stephenson 
( 1 972) demonstrated that rats became tolerant to this effect of nicotine when administered 
daily (0.8 mg/kg) for 4 days and that locomotor activity actually increased after 7 days. 
Using a Y-shaped runway, Stolerman et aI. ( 1973) demostrated that acute and chronic 
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tolerance developed to nicotine's depressant effects in rats. �t has been shown that acute 
administration of nicotine will produce an initial depression of spontaneous activity which 
is followed by stimulation (Clarke and Kumar, 1983; Clarke and Kumar, 1983a; Morrison 
et aI., 1 969). Chronic administration of nicotine has been shown to produce a stimulation 
of locomotor activity (Clarke and Kumar, 1983; Clarke and Kumar, 1983a; Morrison et aI., 
1969). Both acute and chronic effects of nicotine on locomotor activity are dose-dependent 
and are antagonized by mecamylamine, but not hexamethonium, suggesting that this effect 
is centrally mediated. 
Nicotine has been shown to produce antinociception centrally as well. Mattila et aI. 
( 1968) showed that nicotine had anti nociceptive activity in mice and rabbits, and that this 
effect was antagonized by mecamylamine but not altered by physostigmine, atropine, or by 
reserpine pretreatment. Phan et al. ( 1973) showed that mecamylamine would antagonize 
nicotine-induced antinociception in the hot-plate test in mice and rats. Sahley and Berntson 
( 1 979) found that mecamylamine, but not hexamethonium, would antagonize 
nicotine-induced antinociception in mice using the tail-flick assay, and that nicotine's effect 
was greatly enhanced by central administration, suggesting a central site of action. 
Kamerling et aI. ( 1982) found that nicotine given Lv. produced antinociception in the dog 
as measured by a skin-twitch response to a heat stimulus that was not antagonized by 
naltrexone. The potency of nicotine was enhanced by central administration. Using the 
tail-flick assay, Tripathi et al . ( 1982) found that 3 mg/kg of nicotine s.c. produced 
antinociception in mice that was maximal after 5 min. Furthermore, the time course for this 
effect was well correlated with nicotine brain levels. Aceto et aI. ( 1983) demonstrated that 
nicotine, but not its quaternary methiodide derivatives, produced antinociception in rats and 
mice. Mecamylamine was found to antagonize nicotine, but hexamethonium was without 
effect. These investigations therefore suggest that nicotine produces antinociception 
centrally that is antagonized by central nicotinic antagonists. 
Since nicotine-induced alterations of locomotor activity and antinociception are 
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selectively antagonized by central nicotinic antagonists, these compounds are thought to 
have a specific mechanism of action. Although this antagonism is thought to involve 
nicotinic receptors, direct evidence is lacking. Pharmacological criteria for a 
receptor-mediated mechanism of action includes structure-activity relationships. Although 
extensive studies of this nature have been conducted in the periphery, the structural 
requirements for antagonism of the behavioral effects of nicotine have yet to be thoroughly 
documented (Stone et aI . ,  1 962; Bretherick et aI. ,  1 966). Studies addressing the 
structure-activity relationships for nicotine in producing its behavioral effects suggests that 
stereoisomerism plays a minor role and that an intact pyrollidine ring is necessary (Martin, 
1986). Comparisons of the structural requirements for nicotine agonists and antagonists, 
as well as analysis of the structural overlap of these compounds wiII yield insights as to the 
plausability that an antagonist binding site exists and that the agonists share this binding site 
in vivo . 
In order to determine the nature of the antagonism of nicotine by pempidine, the ability 
of pempidine to alter the dose-response relationships of nicotine in producing depression of 
spontaneous activity and antinociception in mice was determined. Dose-response curves 
for nicotine were determined in the presence of increasing doses of the antagonist and 
evaluated for differences in the EDso's and the maximum effect produced by nicotine at 
each dose of pempidine. In addition the structural requirements for mecamylamine's 
antagonism of these effects of nicotine were determined by comparing the potency of 
several mecamylamine analogs to the parent compound. 
Materials and Methods 
� 
Male ICR mice (Dominion Laboratories, Dublin, V A) weighing 24-30 g were used for 
all test procedures, and a minimum of 12  mice were utilized for each dose and time point. 
Mice were maintained on a 1 2-hr light/dark cycle and had free access to Purina Rodent 
Chow (Ralston Purina, St. Louis, MO) and water. 
� 
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L-Nicotine bitartrate was synthesized by Dr. Everette L. May (Virginia Commonwealth 
University). Pempidine was purchased from Sigma Chemical Co. (St. Louis, MO) and 
was converted to its tartrate salt. Mecamylamine HCI was a gift from Merck, Sharp and 
Dohme & Co. The mecamylamine analogs were synthesized by Drs. Everette L. May and 
John Suchoki (Virginia Commonwealth University). All drugs were administered in 0.9% 
NaCI, pH=7.4 as mg free base/kg body weight in a volume of 10 ml/k:g body weight. 
Experimental Procedures 
Mice were placed into individual photocell activity cages (28 x 16.5 cm) immediately 
after sc administration of either 0.9% saline, pH =7 .4 or nicotine bitartrate. They were 
allowed to acclimate for 10 min, and then interruptions of the photocell beams were 
recorded for the next 10 min. Data were expressed as % depression where: 
% depression = 
(counts from nicotine-treated animals! counts from saline-treated animals) x 100. 
Antagonists or saline were administered sc 10 min prior to saline or nicotine bitartrate. 
Dose-response curves were determined for nicotine in the presence of 0, 0.3, 1 .0, and 3.0 
mg/lcg of pempidine. For the structure-activity studies mecamylamine, pempidine and 
mecamylamine analogs were administered sc 10 min prior to an ED84 dose of nicotine. 
The data were expressed as % antagonism where: 
% antagonism = 
[ 1 -(% effect with antagonist pretreatment!% effect with nicotine alone)] X 100. 
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The potency ratios for each compound compared to (±)exo-mecmaylamine were 
determined where: 
potency ratio =ADso of compound! ADso of (±)exo-mecamylamine. 
Tail-flick reaction time to a heat stimulus was determined following drug or saline 
administration using the method of D'Amour and Smith ( 1941 )  as modified by Dewey et 
al. ( 1970). Pre-injection control values (2-4 sec) were determined for each animal. Mice 
were retested 5 min after sc administration of nicotine bitartrate or saline and the latency to 
the tail-flick response was recorded. A 1O-sec maximum latency was set to prevent tissue 
damage. Data were recorded as change in latency between pre- and post-injection testing 
for each animal. Data were expressed as % maximum possible effect (% MPE) where: 
% MPE =[(test latency - control latency)/(1O sec- control latency)] x 100. 
Antagonists or saline was administered sc 10 min prior to saline or nicotine bitartrate. 
Dose-response curves were determined for nicotine in the presence of 0, 0.03, 0. 1 ,  0.3, 
and 1 .0 mg/kg of pempidine. Mecamylamine analogs were evaluated for antagonistic 
potency as described above. 
Data Analysis 
EDso and ADso values with 95% confidence limits (C.L.) and EDs4 values were 
determined by the method of Litchfield and Wilcoxon ( 1949). Dunnett's t-test was used to 
make comparisons between the maximum effects produced by nicotine in the presence of 
saline and each dose of antagonist (Dunnett, 1964). 
llliJ.Ilts 
Penmidine antal:onism 
Nicotine produced a dose-responsive depression in spontaneous activity with an EDso 
of 0.73 (0.49- 1 . 10) mg/kg as can be seen in Figure 2. Pempidine shifted the dose-response 
curve for nicotine to the right in a dose-related manner. The EDso of nicotine was 
increased to 1 .46 (0.95 - 2.25), 3.01 (2. 19 - 4 .14), and 3 .44 (2.06 - 5 .74) mg/kg by 0.3, 
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Figure 2. Antagonism of nicotine-induced depression of spontaneous activity by pempidine 
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1 .0, and 3.0 mg/kg of pempidine, respectively. The increase in the ED50 of nicotine was 
statistically significant from control at 1 .0 and 3.0 mg/kg of pempidine, as determined by a 
lack of overlap in the 95% confidence intervals of the EDso's (figure 2). The maximum 
effect of nicotine was not decreased significantly by pempidine. Pempidine alone had 
slight effects on spontaneous activity at doses the doses studied in that 0. 1 ,  0.3, 1 and 3 
mg/kg produced 21 ( 14), 23 ( 12), 13 (7) and 22(22) % depression, respectively. A 10  
mg/kg dose of pempidine alone produced 63  (4) % depression of spontaneous activity. 
The pattern of shift for nicotine dose-response curves in producing antinociception by 
pempidine was different than for depression of spontaneous activity, as can be seen in 
figure 3. The dose-response curves for nicotine were shifted downward and to the right by 
pempidine. The EDSO of nicotine was increased from 1 .94 (1 .22 - 3.07) mg/kg to 3.72 
(2.03 - 6.8 1 ), 4.67 (2.67 - 8. 1 3), and 26.7 ( 15.25 - 46.54) mg/kg by 0.03, om , and0.30 
mg/kg of pempidine, respectively. The increase in the EDso of nicotine was significant 
with 0.3 mg/kg of pempidine, as can be seen from the lack of overlap in the 95% 
confidence interval of the EDso compared to the saline-pretreated values. The 
dose-response curve for nicotine was shifted even farther to the right by 1 .0 mg/kg of 
pempidine and the highest %MPE that could be obtained was 54% at 30 mg/kg of nicotine. 
Maximum antinociception (100 % MPE) following saline pretreatment was produced by 3 
mg/kg of nicotine. The maximum antinociception that was found in the presence of 0.3 
and 1 .0 mg/kg of pempidine was produced by 30 mg/kg of nicotine and was 75 and 54 
%MPE, respectively. The %MPE for these groups were found to be lower than the group 
given 3 mg/kg of nicotine following saline-pretreatment at the 0.01 level of significance. 
Doses of nicotine greater than 40 mg/kg with 0.3 and 1 .0 mg/kg of pempidine pretreatment 
resulted in convulsions and death. Pempidine alone had no effect on tail flick latency at 
doses up to 10  mg/kg. 
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Figure 3. Antagonism of nicotine-induced antinociception by pempidine 
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Structure-activity relationship 
Nicotine produced depression of spontaneous activity and antinociception with ED84'S 
of 1 .7 1  and 2.56 mg/kg, respectively. The (±)-exo-isomer of mecamylamine antagonized 
the effect of nicotine at these EDs4 doses with ADso's of 0.24 (0. 14-0.42) mg/kg for 
depression of spontaneous activity and 0.08 (0.02-0.29) mg/kg for antinociception. The 
potency of pempidine was not found to be significantly different from that of 
mecamylamine in that the ADso's for depression of spontaneous activity and 
antinociception were 0. 10 (0.06-0.17)  and 0. 13  (0.05-0.29) mg/kg, respectively. The 
potency ratios for pempidine in antagonizing these effects can be seen in Table 1 .  For 
depression of spontaneous activity, (-)-exo-mecamylamine (IIA, Table 1 )  was 
approximately equipotent with its racemic counterpart in that it has an ADso of 
0.42(0.22-0.78) mg/kg. The (+)-isomer (liB) produced a maximum of 40% antagonism 
of the hypoactivity at doses from 0.2 to 1 .0 mg/kg. No antagonism was found at 3.0 
mg/kg of the (+)-isomer due to the fact that this dose produced 55% depression of 
spontaneous activity when given 10 min prior to saline. Therefore, an ADso could not be 
calculated for this compound in this assay. However, both the (-)- and (+ )-antipodes of 
exo-mecamylamine were found to have similar potency to their racemic counterpart for 
antagonism of nicotine-induced antinociception in that their ADso's were found to be 0.09 
(0.04-0.23) and 0.24 (0. 10-0.57) mg/kg, respectively. 
The N-methylated derivative of (±)-exo-mecamylamine (III, table 1) was found to be 
equipotent with the parent compound in that ADso's of 0.33 (0. 1 4-0.75) and 0. 1 7  
(0. 1 1 -0.26) mg/kg were found for depression of spontaneous activity and antinociception, 
respectively. None of these compounds other than (+)exo-mecamylamine were found 
tohave agonist effects in either assay. The importance of the methyl groups in positions 
adjacent to the nitrogen atom in mecamylamine is illustrated in table 1. The racemic 
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Table 1 .  Influence of isomerism and omission of methyl groups from mecamylamine. 
ReI. Potency a 
COMPOUND fr. endoJexo Rt Ih R3 & lis Spont. Act. Antinocicep. 
mecamylamine ± exo H CH3 CH3 CH3 CH3 1 .00 1 .00 
pempidine 0.40 1 .60 
IIA exo H CH3 CH3 CH3 CH3 1 .75 1 . 1 3  
IIB + exo H CH3 CH3 CH3 CH3 _ b  3.00 
III ± exo CH3 CH3 CH3 CH3 CH3 1 .40 2. 1 3  
lYE ± exo H H H H H >40 > 1 25 
IVD ± endo H H H H H >40 > 1 25 
VB ± exo CH3 H H H H >40 >125 
VD ± endo CH3 H H H H >40 > 1 25 
VI ± exo CH3 H H CH3 H 4.92 3 1 .25 
a Relative potency compared to mecamylamine as described in text. 
b ADso could not be detennined for reasons given in Results. 
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isomers of exo- and endo-2-norbomamine (NE and IYD, respectively) were found to be 
inactive up to 10 mg/kg in both assays. The maximum antagonism produced for 
depression of spontaneous activity was 1 0% for the exo-isomer at 1 0  mg/kg. No 
antagonism was seen with the endo-isomer up to the same dose. For antinociception, the 
maximum antagonism that could be produced at 10 mg/kg was 25 and 1 8% for the exo­
and endo-isomers, respectively. The N-methylated counterparts of these compounds (VE 
and YD, table 1 )  were found to be equally inactive. The maximum antagonism of 
nicotine-induced depression of spontaneous activity by the N-methylated derivatives of 
exo- and endo-2-norbomamine was found to be 37 and 17%,  respectively. For 
antinociception, these values were 32 and 66% at 10 mg/kg of the exo- and endo-isomers, 
respectively. None of these compounds had agonistic effects in either assay at 10 mg/kg. 
The addition of one methyl group to the 3-position of VE was found to restore efficacy in 
that compound VI antagonized nicotine-induced hypoactivity and antinociception with 
AD50's of 1 . 1 8  (0.74- 1 .89) and 2.50 ( 1 .22-4.86) mg/kg, respectively (table 1 ) .  
The effect of translocating the methyl groups adjacent to the nitrogen to various 
positions on the norbomane ring is demonstrated in table 2. The 2-desmethyl derivative of 
(±)-endo-mecamylamine (compound VII, Table 2) possesses similar potency to 
(±)-exo-mecamylamine, with ADso's of 0.20 (0. 1 3-0.3 1 )  and 0. 1 3  (0.07-0.27) mg/kg for 
antagonism of nicotine-induced depression of spontaneous activity and antinociception, 
respectively. Translocation of the 2-methyl group to the I -position has little effect on the 
activity of mecamylamine, as can be seen with compounds VIllA and VIIIB. The (-)- and 
(+)-exo-isomers were found to have AD50's of 0.29 (0. 12-0.44) and 0.25 (0. 15 -0.42) 
mg/kg for depression of spontaneous activity, respectively. For antagonism of 
nicotine-induced antinociception, the (-)- and (+ )-exo-isomers were found to have 
respective ADso's of 0.89 (0.43- 1 . 84) and 0.22 (0.09-0.56) mg/kg. Their (-)- (IXA) and 
(+ )-endo (IXB) counterparts had similar potency in that their respective ADso's for 
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Table 2. Influence of transposition of methyl groups of mecamylamine. 
ReI. Potency a 
COMPOUND ±L:. endo/exo &1 &2 &3 & Spont. Act. Antinocicep. 
vn ± endo H H CH3 H 0.80 1 . 60  
VllIA exo CH3 H CH3 H 1 .08 1 1 . 1 0 
VllIB + exo CH3 H CH3 H 1 .04 2.75 
IXA endo CH3 H CH3 H 0.83 1 .50 
IXB + endo CH3 H CH3 H 1 .08 2.38 
X ± exo CH3 H H CH3 4.50 1 2.63 
XM ± exo CH3 CH3 H CH3 8.88 1 2. 1 3  
a Relative potency compared to mecamylamine as described in text. 
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depression of spontaneous activity are 0.20 (0. 1 4-0.30) and 0.26 (0.20-0.34) mg/kg. 
They had similar potency in antagonizing nicotine's antinociceptive effects in that the 
A Dso's of the (-)- and (+)-isomers were found to be 0. 1 2  (0.002-9.66) and 0. 1 9  
(0.02- 1 .60) mg/kg, respectively. Translocation of the 3-gem-dimethyl groups to the 
7-position (compound X, table 2) was found to reduce the potency of mecamylamine in 
that the ADso's for depression of spontaneous activity and antinociception were 1 .08 
(0.50-2.29) and 1 .01  (0.58- 1 .76) mg/kg, respectively. The N-methylated counterpart 
(XM, table 2) was found to have similar potency in that respective ADso's of 2. 1 3  
( 1 . 1 0-4. 1 1 )  and 0.97 (0.76- 1 .24) mg/kg were found for depression of spontaneous 
activity and antinociception. No evidence of agonistic activity was found for any of these 
compounds at the highest dose tested for antagonism. 
The effect of adding a pyridinyl group to the nitrogen atom of mecamylamine can be 
seen in the series of compounds in table 3. These compounds were not found to possess 
full activity up to 10 mg/kg, and therefore the maximum % antagonism found is reported 
since ADso values could not be calculated. None of these compounds were found to 
possess agonistic activity in either assay up to 10 mg/kg. Addition of a pyridinyl group to 
the N-methyl of compound VA (table 1 )  does not increase the activity (XI, table 3) in that 
the antagonism produced by 10 mg/kg of this compound was not significantly greater than 
V A. Furthermore, the antagonism was not dose-responsive at lower doses. Addition of an 
N-methyl (compound XII) to XI or alteration of the methylene group connecting the 
nitrogen to the pyridine ring (compounds XIII and XIV) did not affect the activity as well. 
The antagonism seen with these compounds was variable and not statistically significant. 
Addition of methyl groups to the positions adjacent to the nitrogen was not found to result 
in an increase in antagonism. Addition of a pyridinyl group to the nitrogen of VIIIA (table 
2) through a methylene group (XV A) abolishes the activity of this compound in that no 
significant antagonism was seen in either assay. The (+)-isomer (XVB) as well as the 
40 
Table 3. N-pyridinyl-substituted derivatives of mecamylamine 
Max. Antag. a 
COMPOUND ±/.;. !<ngQ[\<xQ RI R2 & � S1K2nI. A\;I. AnIiIl�i�12. 
XI ± exo H H CH2 H 6 47 
XII ± exo H CH3 CH2 H 9 40 
XIII ± exo H H XI H 0 17  
XIV ± exo H H X2 H 21  48 
XVA exo CH3 H CH2 CH3 12  28 
XVB + exo CH3 H CH2 CH3 30 14  
XVIA endo CH3 H .  CH2 CH3 0 1 0  
XVIB + endo CH3 H CH2 CH3 15  29 
XVIIA exo CH3 CH3 CH2 CH3 28 0 
XVllB + exo CH3 CH3 CH2 CH3 44 27 
a Maximum percent antagonism found at doses up to 10 mg/kg. 
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respective (-)- and (+)-endo isomers (XVIA and XVIB, respectively) were found to be 
inactive up to 10 mg/kg. Addition of an N-methyl group to the (-)- and (+)-exo-isomers 
(XVlIA and XVIIB, respectively) had no effect on their activity. 
4. Discussion 
It has been inferred that ganglionic blockers that penetrate the blood-brain barrier 
antagonize nicotine centrally in a purely noncompetitive fashion based upon the fact that 
they do not displace 3H-nicotine binding in vitro from brain tissue (Martin, 1986). 
However, the correlation between the in vivo pharmacology of compounds and their 
ability to displace radiolabelled ligands from tissue determines the relevance of binding 
data. It is therefore necessary to evaluate the effects of these compounds in the intact 
animal with regard to their competitive or noncompetitive nature. Pempidine shifts the 
dose-response curves for nicotine in producing depression of spontaneous activity in a 
manner consistent with competitive antagonism, since the EDso's of nicotine are increased 
by doses of pempidine that do not alter its maximum effect These data are consistent with 
the findings of Stolerman et al. (1982), in that mecamylamine's antagonism of nicotine in 
decreasing rate of responding in a drug-<iiscrimination paradigm was completely overcome 
by increasing the dose of nicotine. Questions have arisen as to whether the effects of 
nicotine on spontaneous activity are receptor mediated. Stolerman et al. ( 1982) suggested 
that depressant effects are a nonspecific measure of nicotine's central activity. On the other 
hand, the ability of central, but not peripheral, antagonists to block this effect coupled with 
the fact that tolerance develops to the depressant effects of nicotine suggests that specific 
central receptor mechanisms are involved in nicotine's alteration of spontaneous activity. 
However it is possible that nicotine's ability to overcome pempidine's antagonism of 
depression of spontaneous activity may be due to non-receptor mechanisms that are not 
blocked by pempidine. 
The pattern of shift of nicotine dose-response curves by pempidine for the production of 
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antinociception is different from what was found for depression of spontaneous activity 
and is strikingly similar to that reported by van Rossum et al. ( 1962) in the guinea pig 
jejunum. This type of antagonism was termed by van Rossum as "dualistic" antagonism, 
in that both the characteristics of competitive and noncompetitive antagonism are displayed. 
It is not clear from van Rossum's data if there is a dose of pempidine that alters the EDso of 
nicotine while failing to alter its maximum effect, as statistics were not reported for these 
measures. In this study, it is clear that at doses of pempidine where the EDso of nicotine is 
significantly increased, the maximum effect that can be obtained with nicotine is decreased. 
This suggests that pempidine acts noncompetitively to antagonize nicotine-induced 
antinociception in the mouse. The mouse tail-flick assay has an advantage in that the range 
of doses of nicotine that can be studied is not as limited as it is for some behavioral tests. 
The maximum dose of nicotine that can be used in drug-discrimination studies with nicotine 
is limited due to rate-suppressive effects at higher doses that are not antagonized by 
mecamylamine. This is not a trivial point when one is atttempting to determine if the 
antagonism can be completely reversed by increasing the dose of the agonist. However, in 
vivo assays possess limitations in predicting the mechanism of action of compounds. 
Obviously, many events occur following the administration of a compound other than 
receptor activation or blockade. The researcher has less control over the metabolism and 
distribution of compounds in vivo than in vitro. Nicotine produces changes in many 
neurotransmitter systems and changes in behavior following nicotine administration 
undoubtedly occur as a result of effects on more than one system. An example of one such 
limitation in this study is the range of pempidine doses that could be tested in the 
spontaneous activity assay. The range of doses of pempidine was limited due to its 
depressant effects. This may account for the inability to find a decrease in the maximum 
depression produced by nicotine following pempidine pretreatment 
The difference in the nature of pempidine's antagonism of these effects may also be due 
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to multiple mechanisms of either nicotine or pempidine. Pempidine may compete for a 
select subset of nicotine binding sites that are responsible for nicotine's depressant effects 
and that have not been elucidated under the conditions that have been studied for agonist 
binding in vitro to brain tissue. Another explanation that may attribute for the discrepancy 
between pempidine's ability to antagonize nicotine's depressant and antinociceptive effects 
is noncompetitive antagonism of spare receptors. This theory, first proposed by 
Stephenson (1956), assumes that the maximum possible effect that can be achieved with a 
compound depends upon both the number of available receptors and the physiological 
limits of the responding tissue. A spare receptor pool exists when the tissue responds 
maximally while only a fraction of the total receptor pool is occupied. A decrease in the 
maximum response is seen only when the receptor pool is depleted to a crltical level by a 
noncompetitive antagonist. This theory has been supported by the studies of Furschgon 
(1955) and Nickerson ( 1956). The pattern of the shift of the nicotine dose-response curves 
in producing depression of activity by pempidine is consistent with this model. The lack of 
pempidine's ability to decrease the maximum possible effect of nicotine-induced 
hypoactivity may indicate that the spare receptor pool for this effect is not sufficiently 
depleted by doses of pempidine up to 3 mg/kg. Studying the binding of the agonists as 
well as antagonists under in situ or in vivo conditions may provide insights as to which of 
these explanations best accounts for the antagonism of nicotine-induced depression of 
spontaneous activity and antinociception by pempidine. 
The structural alterations made in the mecamylamine molecule reveal the positions 
within the molecule that are important for its antagonistic activity. TIle compounds in table 
1 clearly demonstrate that the methyl groups in the N and 3 positions are crucial for 
activity. It is further illustrated in table 2 that at least 3 methyl groups must be present at the 
N, 1 , 2 and 3 positions for optimal potency. Furthermore compounds X and XM in table 2 
demonstrate that the presence of methyl groups in the 7- as opposed to the 3-position 
significantly reduces the potency, possibly due to increased sterlc hindrance of the 
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nitrogen. Table 3 clearly shows that addition of bulky substituents to the nitrogen reduces 
the activity of these compounds. One finding that was consistent with all compounds 
tested was the lack of effect of stereoisomerism on their activity and potency. This can be 
seen by comparing all compounds that differ in designation by A or B, with A consistently 
denoting the (-)-isomer and B denoting its (+)antipode. The data show that exo/endo 
isomerism is without effect on the activity and potency of these compounds as well. These 
findings are in agreement with those of Stone et aI. ( 1 956) for antagonism of 
nicotine-induced convulsions and pupil dilitation in mice. These investigators found that of 
the N, 2 and 3 methyls and the methylene bridge, at least three must be present for optimal 
activity and potency. Furthermore, increasing the bulk of the N-substitution decreased the 
potency of the antagonists in these assays. They likewise found that stereoisomerism had 
little effect on the potency of all analogs tested. Therefore, the activity and potency of 
mecamylamine seems to depend only upon the presence and position of the methyl groups 
adjacent to the nitrogen atom in both the CNS and at the ganglia 
The methyl groups may serve two possible roles in the activity and potency of 
mecamylamine. They may serve to provide steric bulk to block a binding site or ion 
channel, or as electron-donating groups that increase the base strength of the nitrogen. 
Bretherick et aI. ( 1962) examined the structure-activity relationships of a number of 
pempidine analogs for antagonism of nicotine-induced contractions of guinea-pig ileum. 
They found that attachment of electron-donating groups to the nitrogen atom in pempidine 
increased potency, whereas electron-withdrawing groups in this position decreased 
potency. Therefore the base strength of the nitrogen atom in these compounds appears to 
be important for their potency. 
Such meager structural requirements for the activity of mecamylamine suggests that, if 
a binding site exists for these compounds, it is not likely to be the agonist binding site. The 
nitrogen of mecamylamine is not contained within a ring, which was found to be necessary 
for agonistic activity (Chance et aI. ,  1978). Furthermore, the pyrrolidyl nitrogen of 
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nicotine is in close proximity to the pyridine ring, and increasing the distance between the 
two has been shown to decrease the activity of nicotinic agonists (Chance et aI. ,  1978).  
Addition of such a moiety to active structural isomers of mecamylamine was found to 
abolish activity suggesting that the nitrogen cannot gain access to its site of action with such 
bulky substituents in place. These [mdings lend support for noncompetitive antagonism of 
nicotine by these compounds, as it does not appear that the agonists and antagonists 
possess similar structural requirements for their activity. 
III. Receptor Binding Interactions of Nicotinic Agonists and Antagonists 
Introduction 
The existence of "receptive substances" for the action of nicotine was ftrst proposed by 
Langley ( 1 905) as a result of observations regarding nicotine's ability to contract skeletal 
muscle. Since that time, nicotinic receptors have been postulated at the autonomic ganglia 
and in the brain as well Originally, evidence for the existence of central nicotinic receptors 
was that nicotine produced a myriad of behavioral effects that were selectively antagonized 
by ganglionic-blocking agents that penetrated the blood-brain barrier. Since the early 
1970's numerous attempts have been made to characterize a nicotinic binding site to brain 
tissue. A variety of cholinergic agonists and antagonists, as well as a-neurotoxins and 
nicotine itself have been used. This subject has been reviewed in detail by Martin ( 1986). 
The relevance of the nicotine binding sites that have been characterized in brain remain 
in question with regard to nicotine's pharmacology. One of the most consistent ftndings is 
that none of the central nicotinic antagonists, such as mecamylamine and pempidine, 
displace 3H-nicotine binding to brain. Although this suggests that these compounds act as 
noncompetitive antagonists, pharmacological studies that address this issue have led to 
ambiguous ftndings. Mecamylamine has been shown to possess both competitive and 
noncompetitive characteristics in its antagonism of nicotine at the ganglia (van Rossum et 
al. , 1 962) and in the eNS (Stolerman et al. , 1 987). It has also been shown that the nicotinic 
receptor can exist in a variety of states. �ome of these states are termed "desensitized" 
states due to the fact that agonist binding does not lead to receptor activation. Many 
investigators have postulated that the nicotine binding sites characterized to date in vitro are 
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in fact desensitized receptors. 3H-Nicotine binding in situ to brain slices has been 
characterized by a number of investigators (Marks et al. ,  1986; Clarke et ai. ,  1984). 
However, the sensitivity of these binding sites to displacement by the central nicotinic 
antagonists has not been documented. Binding studies with radiolabelled reversible 
ganglionic blockers such as mecamylamine and pempidine in vitro and in situ have not been 
documented as well. 
Over the last decade, quantitative receptor autoradiography has proven to be a valuable 
tool for the determination of radioligand binding to discrete brain areas. It has been applied 
to the study of many receptor-ligand interactions, including nicotine. An excellent review 
on the methods, advantages and possible pitfalls of this technique has been provided by 
Kuhar ( 1985). Other pertinent methodological considerations regarding tritium 
quantitation by the use of tritium-sensitive films has been provided by Geary et al. ( 1985) 
and Geary and Wooten (1985). Quantitative autoradiography allows the investigator to 
study radioligand localization patterns in situ using tissue slices. This method offers 
advantages over classical in vitro methods in that the architecture of the tissue remains 
intact and quantitation is more sensitive in that discrete brain areas may be studied. The 
advent of computerized densitometry has rendered the technique even more amenable to 
standardization and quantitation (Goochee et ai. ,  1980). Nicotinic receptors have been 
studied autoradiographically using these techniques by a number of investigators (Clarke et 
al., 1985a; Segal et al., 1978; Duggan et al .• 1976). The pattern of localization in brain 
that has been found for 3H-nicotine is consistent for all of these studies. Furthermore, the 
localization pattern of 3H-nicotine binding sites is identical to that of 3H-acetylcholine in the 
presence of a muscarinic antagonist (Clarke et al., 1985a). The effect of the antagonists on 
3H-nicotine binding in situ to any of these brain areas remains to be documented 
autoradiographically. 
Therefore in situ studies were carried out to determine the sensitivity of 3H-nicotine 
binding to displacement by nicotinic antagonists using rat brain. The characteristics of 
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3H-nicotine binding were compared in situ and in vitro. The in situ 3H-nicotine binding in 
the presence and absence of nicotinic antagonists was further quantitated 
autoradiographically in discrete brain areas. The binding characteristics of 3H-pempidine 
were determined in vitro and in situ to rat brain for comparison with those of the agonists 
and to test the hypothesis that the agonists and antagonists may share binding sites that 
have not been elucidated to date. 
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Materials and Methods 
� 
Male ICR mice (Dominion Laboratories, Dublin, VA) weighing 1 8-25 g were used for 
the in vitro binding experiments. Male Sprague-Dawley rats (Dominion Laboratories, 
Dublin, VA) weighing 200-250 g were used for in situ binding and autoradiography 
experiments. All animals were kept on a 12 hr light/dark cycle and given Purina Rodent 
Chow (Purina Inc., St. Louis, MO) and water ad libitum. 
Materials 
[3H]-L-Nicotine (80 Ci/mrnol) was purchased from New England Nuclear (Boston, 
MA), and purity was determined by thin-layer chromatography (methanol:chloroform: 
ammonium hydroxide, 70:30:0.2). pH]-Pempidine (80 Ci/mmol) was a gift from Dr. 
Richard Young, New England Nuclear (Boston, MA), and purity was determined by 
thin-layer chromatography as described for [3H]-L-nicotine and by HPLC using a 
Flo-one\Beta radioactive flow detector (Radiomatic Instr. and Chern. Co., Inc. ,  Tampa, 
FL). (-)-Nicotine and (+)-nicotine were kindly donated by Dr. Everette L. May of Virginia 
Commonwealth University (Richmond, VA) as their bitartrate salts. (-)-Cotinine was a gift 
from Dr. Edward Bowman of Virginia Commonwealth University. (±)-Atropine sulfate, 
bethanechol hydrochloride, hexamethonium, (±)-anabasine, (-)-cytisine, mecamylamine 
and pempidine were purchased from Sigma Chemical Co. (St. Louis, MO). 
PH1-L-Nicotine bindin� in vitro 
PH]-L-Nicotine binding was performed in vitro according to the method of Scimeca 
and Martin ( 1 988) with minor modifications. Tissue homogenate was prepared from 
whole mouse brain (minus cerebellum) in 10  volumes of ice-cold 0.05 M Na-K phosphate 
buffer (pH 7 .4) and centrifuged ( 1 7500 g, 4 0c) for 30 min. The pellet was then 
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resuspended in 20 volumes of ice-cold glass-distilled water and allowed to remain on ice 
for 60 min before being centrifuged as before. The resulting pellet was then resuspended 
to a final tissue concentration of 40 mg/ml of buffer. To various concentrations of 
[3H]-L-nicotine was added 0.5 ml of tissue homogenate for a fmal incubation volume of 1 
ml. Specific binding was defined as the difference in the amount of binding in the presence 
and absence of 100 IJ.M L-nicotine tartrate and determinations were made in triplicate. The 
tissue was incubated for 2 hr at 4 °C and then rapidly fIltered through Whatman GF/C filter 
discs (previously soaked overnight in 0. 1 % poly-I-lysine) using a vacuum manifold 
(Millipore Corp., Bedford, MA). Following three consecutive washes with ice-cold 
buffer, the fIlter discs were allowed to air dry and then placed in scintillation vials with 1 0  
ml of Budget-Solve (Research Products International Corp., Mt. Prospect, IL). The vials 
were vigorously shaken for 1 hr and then counted by scintillation spectrometry. 
Correction for quench was by external standardization. Following transformation of the 
data by the method of Scatchard (1949) the K.! and Bmax values were determined using the 
LIGAND program of Munson and Rodbard (1980) supplied by NllI. 
Displacement of pH]-L-nicotine binding at 1 nM was determined in the presence of 
increasing concentrations of various ligands and converted to % displacement where: 
% displacement = binding displaced by ligand concentration + binding 
displaced by 100 IJ.M nicotine tartrate. 
The ICso's were determined from a plot of the log concentration vs. %displacement and 
converted to � values by the method of Cheng and Prusoff (1973). 
PHl-L-Nicotine bindin!: in situ 
Rats were decapitated and their brains quickly removed and frozen in isopentane at -60 
5 1  
°C. The brains were then mounted onto cryostat chucks and stored at -70 °C until 
sectioned. Following equilibration of the mounted brain at -20 °C for 1 hr, 20 � sections 
were taken and thaw-mounted onto slides coated with 0.5 % gelatin (w/v) and 0.05% 
chromium potassium sulfate (w/v). The sections were stored overnight under vacuum in a 
dessicator at 4 °C and used for binding studies the following day. Sections containing 
primarily frontal cortex and caudate putamen (A8900-A6300, Konig and Klippell, 1963) 
were used for the binding isotherms and Scatchard analysis, as these sections have no 
longitudinal gradient of binding for [3HJ-L-nicotine (Clarke and Pert, 1985). The slides 
were placed in slide mailers (Thomas Scientific, Swedesboro, NJ) and incubated as 
described for the in vitro assay. Following incubation, the slides were removed, placed in 
staining racks and carried through four consecutive 500 ml washes of ice-cold buffer. The 
sections were then removed by wiping the slides twice with Whatman GF/C filters. The 
duplicate fIlters were then placed in the same scintillation vial, solubilized overnight with 1 
ml of TS-2 (Research Products International Corp., Mt. Prospect, IL). The samples were 
then acidified with 1 ml of IN HCI and counted by scintillation spectroscopy in 10  ml of 
Budget-Solve (Research Products International Corp., Mt. Prospect, IL). Correction for 
quench was by external standardization. The data were analyzed as described above. The 
amount of protein per section was determined by the method of Bradford ( 1976) by 
collecting 5 adjacent sections and homogenizing in 1 ml of buffer. 
Displacement studies were performed as described for the in vitro assay using 2 nM of 
[3H]-L-nicotine. The data were analyzed in the same manner as well. 
PHl-kNjcotine Autoradiomwhy 
Autoradiograms of the [3HJ-L-nicotine binding to various sections were obtained by 
using conditions identical to the in situ assay and a 10  nM radioligand concentration. 
Nonspecific binding was assessed in the presence of 1 00 �M nicotine tartrate. 
Displacement of this binding was also assessed in all areas in the presence of 100 �M 
pempidine tartrate. Instead of wiping the sections from the slides following the washes, 
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the slides were rapidly dried under a stream of cool, dry air and placed in a dessicator under 
vacuum at 4 °C overnight to assure unifonn hydration. The sections were then apposed in 
duplicate to tritium-sensitive film (Hyperfilm_3H, Amersham Corp., Arlington Hts. , IL) 
along with a range of tritium standards (0. 1 14-9.468 nCi/mg) rH-microscales, Amersham 
Corp., Arlington Hts., IL) for 10 weeks. All studies were conducted in triplicate. Section 
designations were made according to the nomenclature of Konig and Klippel ( 1963), where 
the number of microns rostral to an FO plane is given, so that larger numbers represent 
more rostral sections. The FO plane is defined as the plane dividing the diencephalon and 
the mesencephalon. The autoradiograms were quantitated using a computerized 
densitometric system (MCID System, Imaging Research Inc., Toronto, Canada) and an 
mM PC. The % displacement was calculated as described above. 
Calibration of 3H-microscales aeainst brain paste standards 
The 3H-microscales were calibrated against brain paste standards to correct for tritium 
quench. Brain paste was obtained by homogenizing 3 rat brains in 1 mI of deionized 
water. The paste was then centrifuged for 30 min to remove air bubbles. Aliquots were 
weighed into microfuge tubes and 50 J.Ll of various concentrations of PHl-L-nicotine were 
added for final standard values of nCi/mg tissue, wet weight. The paste standards were 
then vonexed for 5 min and centrifuged for 1 0  min to remove any air bubbles. Actual 
standard values were then obtained by weighing aliquots of the radioactive brain paste 
standards on Whatman GF/C filters, which were then solubilized and counted as described 
for the tissue sections. The standards were then immersed in liquid nitrogen, mounted onto 
cryostat chucks. Triplicate 20 �m sections were taken of each brain paste standard, 
thaw-mounted onto gelatin-coated slides and stored as described for the autoradiographic 
sections. The brain paste standards and 3H-microscales were then apposed to the 
tritium-sensitive film for 10 weeks. Values for the 3H-microscales were obtained by fitting 
a third degree polynomial equation to the brain paste standards and these calibrated values 
were used for quantitation of the radioactivity in each brain area. 
pm-Pempidine bindin� in vitro and in siw 
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[3H]-Pempidine binding to mouse brain was assessed in vitro using the assay 
conditions described for PHl-nicotine. This binding was further assessed with alterations 
of time, temperature, buffer and protein concentration. Displacement of 1 nM of 
[3H]-pempidine by various concentrations of nicotine and pempidine was assessed as 
described for [3Hl-nicotine in vitro. PHl-Pempidine binding to rat brain was assessed in 
siw as described for PHl-nicotine. The time course of PHl-pempidine binding was also 
assesed in siw at 4, 25 and 37 °e. Using assay conditions for pH]-nicotine binding, 
pH]-pempidine binding was assessed to sections from A IO,OOO to A1200 (Konig and 
Klipell, 1963). PHl-pempidine binding was assesed in situ as described for PHl-nicotine 
binding using two alternate buffers of 10 mM HEPES or 50 mM Tris. Displacement of 1 
nM of pH]-pempidine by various concentrations of nicotine and pempidine was assessed 
as described for [3Hl-nicotine in siw. 
Pm-kNicotine bindin� in vitro and in siw 
PH]-L-Nicotine was found to label two binding sites in mouse brain in vitro . As can 
be seen in figure 4, PHl-L-nicotine bound to brain homogenate in vitro in a concentration 
dependent manner and displayed the characteristics of two binding sites, as can be seen by 
the Scatchard transformation of the isotherm. The specific binding ranged from 45 to 85% 
of the total binding. The binding appears to approach saturation at 10 nM, however the 
binding increases linearly at concentrations higher than 20 nM. Resolution of the Scatchard 
plot yields K.J and Bmax values of 0.9 nM and 12 fmoVmg protein, respectively for the high 
affmity site. The low affinity site was found to have a K.! of 194 nM and Bmax of 1 265 
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Figure 4. 3H-L-Nicotine binding to mouse brain homogenate in vitro . 
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fmoVmg protein. 
PH1-L-Nicotine binding was found to display similar characteristics in situ to rat brain 
slices as can be seen in figure 5. The binding was saturable and the specific binding was 
found to be 65 to 90% of the total. Transformation of the isotherm gave yield to a 
curvilinear Scatchard plot as with the in vitro binding. Resolution of the Scatchard plot 
resulted in K.J and Bmax values of 2 nM and 67 fmoVmg protein, respectively, for the high 
affmity site. These values for the low affinity counterpart were found to be 99 nM and 482 
fmoVmg protein, respectively. The in situ binding of pHl-L-nicotine was selective to 
displacement by nicotinic agonists, as can be seen in figure 6. Displacement of this binding 
by the nicotinic agonists (-)-cytisine, (-)-nicotine, (+)-nicotine and (±)-anabasine gave Ki 
values of 0.5, 2.5, 42 and 94 nM, respectively. Displacement with the muscarinic 
compounds (±)-atropine and bethanechol resulted in Ki values of 14 and 6.4 �M, 
respectively. The � for hexamethonium was 76 �M, whereas (-)-cotinine, pempidine and 
mecamylamine did not compete for this binding effectively as their � values were greater 
than 1 000 �M. 
Autoradio�phy of PHl-knicotine bjndin� 
Quantitation of autoradiograms of in situ [3Hl-L-nicotine binding to various sections 
resulted in the data presented in tables 4, 5 and 6. The data presented in table 4 
demonstrates the localization pattern of nicotinic receptors in sections A l  0,000 to A6200, 
consisting primarily of frontal cortex and caudate putamen (figure 7). The largest number 
of nicotinic receptors were found in the septal nucleus (sl), cortex (COR) and caudate 
putamen (cp) and the specific binding ranged from 65 to 82% of the total for these regions. 
Although some displaceable binding was found in the fornix (F), it represented only 43% 
of the total. The specific binding found in the corpus callosum (TCC and RCC), anterior 
commisure (CA), globus pallidus (GP) and triangular septal nucleus (ts) was less than 14% 
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Figure 7. Anatomical map of section A7roJ (Konig and KlippeU, 1963) 
Table 4. Distribution of 3H-L-Nicotine binding and displacement by perilpidine to sections 
A 1O,roJ - A6200 
Displaced a 
Brain area � Pempidine 
COR 5.344 (2. 1 39) 3 . 165 ( 1 .244) 
cp 4.27 1 ( 1 .670) 2.62 1 (0.800) 
sl 7.809 (3.299) 6.046 (3.000) 
F 2.956 ( 1 . 1 14) 1 . 3 15  (0.783) 
TCC 0.534 (0.3 10) 0.366 (0.354) 
RCC 0.7 1 3  (0.358) 0.053 (0.053) 
CA 1 .473 (0.385) 0.998 (0.5 1 3) 
OP 0.619 (0.536) 0.384 (0.259) 
15 0.909 (0.909) 0.8 19  (0. 8 19) 
a Mean (s.e.m.) fmoVmg wet weight tissue 
% Displacement b 
59 
61  
77 
44 
69 
7 
68 
62 
90 
b % displacement with l00 !J.M of pempidine as defined in text 
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of the total binding. Pempidine was found to compete for the pH]-L-nicotine binding most 
effectively in the septal nucleus, cortex and caudate putamen, with 77, 59 and 61 % 
displacement, respectively. There was little displacement by pempidine in the other areas 
of these brain sections. An anatomical map of these areas is shown in figure 7. 
The localization pattern of nicotinic receptors in sections A5700 to A4000, which are at 
the level of the thalamus and hippocampus is shown in table 5. The largest number of 
nicotinic receptors were found in the medial habenula (mh), dorsolateral geniculate bodies 
(dcgl) and lateroventral and ventrodorsal thalamic nuclei (tl and tvd), followed by the 
ventrolateral thalamic nuclei (tv) and the cortex (COR). Little specific binding was found in 
the hippocampus (HI) and hippocampal funiculus (FH). Displacement of this binding by 
100 JlM of pempidine was greatest in the medial habenula, dcgl, thalamic nuclei and 
cortex, and least in the hippocampus and hippocampal funiculus. An anatomical map of 
these regions is demonstrated in figure 8 and representative autoradiograms are shown in 
figure 9. 
Table 5. Distribution of 3H-L-Nicotine binding and displacement by pempidine to sections 
A5700 - A4000 
Displaced a 
% Dis.placementb Brain area � Pempidine 
COR 1 1 .369 (4.288) 9.68 1 (5.536) 85 
HI 6.448 (3.925) 6.009 (4.346) 93 
FH 0.285 (0. 146) 0. 173 (0. 1 58) 61 
mh 56.854 ( 10. 1 36) 41 .325 ( 19.566) 73 
dcgl 3 1 .559 (5.41 6) 23.066 ( 12.268) 73 
tl 22.573 (3. 129) 1 1 .95 1 (8. 1 68) 53 
tvd 1 6.259 (2.624) 8 .9 1 6  (5.760) 55 
tv 10.469 ( 1 .410) 5. 1 36 (2.761)  49 
a Mean (s.e.m.) fmoVmg wet weight tissue 
b % displacement with 100 J.1M of pempidine as defined in text 
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Figure 8. Anatomical map of section A4400 (Konig and KlippeU, 1963) 
Figure 9. Representative autoradiograms of 3H-L-nicotine binding to section A4400 
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The localization pattern of nicotinic receptors in sections A2400 to A 1 200 is 
demonstrated in table 6. The greatest amount of rH]-L-nicotine binding was found in the 
interpeduncular nucleus (IPN), superficial gray layer of the superior colliculus (SGS), 
medial geniculate bodies (mcgm), substantia nigra pars reticulata (SNR) and cortex (COR). 
The specific binding in these regions represented 66 to 96% of the total binding. Less 
binding was found in the hippocampus (HI), reticular formation (FOR) and the dorsal 
commissure of the hippocampus (CFD) and the displaceable binding was only 52, 47 and 
32% of the total for these areas, respectively. The greatest degree of pempidine 
displacement oPH-L-nicotine binding was in the interpeduncular nucleus, superficial gray 
of the superior colliculus, medial geniculate bodies, substantia nigra pars reticulata and 
cortex. Pempidine did not displace a significant amount of binding in the hippocampus and 
dorsal hippocampal commissure. An anatomical map of these regions is demonstrated in 
figure 10 and representative autoradiograms are shown in figure 1 1 . 
Table 6. Distribution of 3H-L-Nicotine binding and displacement by pempidine to sections 
A2400 - AI200 
Displaced a 
% Displacementb Brain area � Pempidine 
COR 5.838 (2. 190) 3 .594 ( 1 . 1 84) 62 
HI 2.946 ( 1 .928) 2.23 1 ( 1 .4 16) 76 
CFD 0.973 (0.396) 1 .050 (0.620) 108 
SGS 20.053 (4.878) 12.273 (7.689) 62 
mcgm 1 1 .254 (4. 196) 8.509 (3.828) 76 
SNR 6.325 (2.744) 4.500 ( 1 . 874) 7 1  
FOR 2. 156 ( 1 . 806) 1 .628 ( 1 . 386) 76 
IPN 75.865 ( 1 2.2 14) 47 . 1 1 6 (25.878) 62 
a Mean (s.e.m.) fmoVmg wet weight tissue 
b % displacement with 100 jlM of pempidine as defined in text 
CFD 
III 
IPN 
w.,,""-"I�-...J-- mcgm 
FOR 
SNR 
Figure 10. Anatomical map of section A 1 800 (Konig and Klippell. 1963) 
Figure 1 1 . Representative autoradiograms of 3H-L-nicotine binding to section A 1 800 
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The displacement of [3H]-L-nicotine binding was also assessed in the presence of a 
range of nicotine and pempidine concentrations in those areas containing the largest number 
of nicotinic receptors. The % displacement of 3H-L-nicotine binding to various areas in 
section A 7000 by 1, 10, and 100 jlM of nicotine and pempidine can be seen in figure 12.  
Nicotine competed effectively for this binding at all concentrations and displaced 78 ± 6, 77 
± 6, and 49 ± 10 % of the total binding in the cortex, caudate putamen, and septal nucleus, 
respectively, at a concentration of 100 jlM. The respective values for pempidine at this 
concentration were 12 .2 ± 4.3, 8.2 ± 3. 1 ,  and 4 ± 4. At 1 jlM, the amount of 
3H-L-nicotine binding displaced by pempidine was 7 ± 4, 8 ± 6, and 1 ± 1 % of the total in 
the cortex, caudate putamen, and septal nucleus, respectively. These values for 1 jlM of 
nicotine were not different from those found with 100 jlM. 
A similar pattern is seen with the other two remaining sections, as can be seen with 
section A4400 in figure 1 3  and with section A1 800 in figure 14. Nicotine competed for 
3H-L-nicotine binding effectively in the cortex, various thalamic nuclei, and medial 
habenula, as can be seen in figure 13 .  Pempidine displaced only 7 ± 3, 8 ± 5, 4 ± 2, 14 ± 
4 and 6 ± 1 % of the total 3H-L-nicotine binding in the cortex, lateroventral thalamic 
nucleus, ventrodorsaJ thalamic nucleus, ventrolateral thalamic nucleus and medial habenula, 
respectively, at a concentration of 100 jlM. Figure 14 also demonstrates the inability of 
pempidine to compete effectively for 3H-L-nicotine binding to the cortex, hippocampus, 
superior colliculus, medial geniculate body, interpeduncular nucleus and reticular formation 
at this relatively high concentration. As with the two preceding sections, nicotine was 
found to compete effectively for this binding at all concentrations studied. 
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Figure 12. Displacement of 3H-L"nicotine binding to regions in section A 7000 by nicotine ( D) 
and pempidine ( . ). 
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Figure 1 3. Displacement of 3H-L-nicotine binding to regions in section A4400 by nicotine ( D) 
and pempidine ( . ). 
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Figure 14. Displacement of 3H-L-nicotine binding to regions in section A 1 800 by nicotine ( D) 
and pempidine ( . ). 
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PHJ-Pempidine bindin� to rat brain in vitro and in situ 
The binding of 3H-pempidine to mouse brain homogenate was studied under a number 
of conditions in vitro. Under the same conditions used for 3H-L-nicotine binding, 
3H-pempidine was not found to bind in a manner consistent with receptor binding, as can 
be seen in figure 15 .  Pempidine did not displace 1 nM of 3H-pempidine from brain 
homogenate in a saturable manner as the greatest amount of displaceable binding was only 
5% of the total binding at 1O �. The time course of 3H-pempidine binding was assessed 
at 37 °C. The greatest amount of displaceable 3H-pempidine binding in the presence of 10 
11M pempidine was found at 90 min and represented only 30 ± 3 % of the total binding. 
Increasing the number of washes of the filters with ice-cold buffer did not significantly 
increase the % specific binding. 
Investigation of 3H-pempidine binding in situ to rat brain slices under a number of 
conditions led to similar results as in vitro. 3H-Pempidine binding under the same 
conditions as 3H-nicotine produced an isotherm and Scatchard plot inconsistent with 
receptor binding, as can be seen in figure 1 6. The time course of 3H-pempidine binding 
was also assessed at 4, 25 and 37 °C. At no time or temperature was the displaceable 
binding found to be greater than 40 % of the total binding. No significant difference was 
found in the ability of 3H-pempidine to bind to various brain sections from AlO,OOO to 
A 1200 as well. Athough the greatest amount of specific binding was found in sections rich 
in thalamic nuclei, it represented less than 35 % of the total binding. Varying the time of 
wash from 2 sec to 2 min did not significantly increase the percentage of specific binding. 
Nicotine was found to increase the amount of displaceable 3H-pempidine binding, which 
was neither concentration nor temperature dependent The greatest amount of displaceable 
3H-pempidine binding was found with 50 nM nicotine at 4 °C and represented only 25 % 
of the total binding. Utilizing a 10 mM HEPES buffer or a 50 mM Tris buffer, both at 
pH=7.4, did not result in an increase in the amount of 3H-pempidine binding. 
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Figure 15 .  3H-Pempidine binding to mouse brain in vitro 
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Figure 16. 3H-Pempidine binding to rat brain in situ 
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Discussjon 
The characterization of central 3H-L-nicotine binding sites in vitro and in situ revealed 
similar findings. The K.! and Bmax values for the two 3H-L-nicotioe binding sites in vitro 
and in situ were found to be similar. Also, the displacement of 3H-L-nicotine binding to 
the high-affinity binding site by various cholinergic compounds was similar to what has 
been found in vitro (Marks and Collins, 1982; Scimeca and Martin, 1988).  Neither 
cholinergic agonists nor antagonists have been found to displace 3H-L-nicotioe binding to a 
low-affinity binding site (Scimeca and Martin, 1988) .  The nicotinic antagonists 
hexamethonium, mecamylamine, and pempidine were not found to compete for this 
binding in situ with high affmity. Similar findings in vitro have led some investigators to 
conclude that these compounds act as noncompetitive antagonists in the CNS (Marks and 
Collins, 1982), although pharmacological evidence is lacking. Romano and Goldstein 
( 1980) have suggested that the long incubation times used for agonist binding may shift the 
receptor into an agonist-selective state, and that binding studies may be a poor indicator of 
mechanism of action. Another possibility is that the homogenization of the brain tissue 
alters the 3H-L-nicotine high-affinity binding site in a manner that renders it 
antagonist-insensitive. The inability of the antagonists to displace 3H-L-nicotine binding to 
brain slices suggests that homogenization alone does not render the high-affmity binding 
site antagonist-insensitive. 
Autoradiographic localization of 3H-L-nicotine binding to brain slices revealed a pattern 
consistent with that reported previously (Clarke et al. ,  1984; Marks et al. ,  1986a) . 
3H-L-Nicotine binding sites were found to be most plentiful in regions containing 
cholinergic innervation (Hoover et al. ,  1978; Armstrong et al. ,  1983; Mesulam et al. ,  
1983). The most dense labelling was found in the interpenduc1ar nucleus, and several 
investigators have found evidence for cholinergic innervation of this area (Lake, 1973; 
7 1  
Cuello e t  al. ,  1978; Sastry,1978; Ogata, 1979; Sastry et al. ,  1979; Vincent e t  aI., 1980). 
An increase in fIring rate of neurons has been found following ionophoretic application of 
acetycholine and carbachol into the interpeduncular nucleus of rats (Brown et aI. ,  1 983). 
The action of both of these compounds was antagonized by hexamethonium, 
d-tubocurarine, and mecamylamine. Similar results were found in rat brain slices with 
carbachol. This study suggests that functional nicotinic receptors are contained in the 
interpeduncular nucleus and that mecamylamine acts to antagonize the effects of agonists on 
neurons in this area. Pempidine, however, was not found to compete in situ for 
3H-L-nicotine binding in this region with relatively high affinity, as can be seen in fIgure 
14 .  
Dense labelling of  the medial habenula and striatum was also found with 3H-L-nicotine. 
The medial habenula has been shown to project cholinergic efferents to the interpeduncular 
nucleus and receive afferent innervation from the nucleus triangularis septi as well as other 
nuclei from the postcommissural septum (Herkenham and Nauta, 1977). SpecifIc 
interactions between nicotine and nicotinic antagonists have not been documented in this 
region. The effects of nicotine on neurons in the striatum have been documented by a 
number of investigators. Giorguieff et al. ( 1975) found that acetylcholine and carbachol 
increased the release of newly synthesized dopamine in vitro from rat striatal slices and in 
vivo from cat caudate nucleus and that both agonists were antagonized by mecamylamine. 
Giorguieff et al. ( 1976) likewise demonstrated that pempidine would antagonize 
acetylcholine's stimulation of dopamine release from rat striatal slices. As can be seen in 
fIgures 12 and 1 3, pempidine did not compete effectively for 3H-L-nicotine binding to 
either of these sites. 
Collinridge and Davies ( 1980) have demonstrated that acetylcholine increases the fIring 
rate of neurons in the substantia nigra pars reticulata. Nicotine has also been shown to 
increase the fIring rate of neurons in the substantia nigra pars reticulata in rats when 
administered by either iontophoresis or subcutaneous injection (Lichtensteiger et al. ,  1982). 
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Iontophoresis of dihydro-Il-erythroidine into this region antagonized nicotine's effect. 
Clarke et al. (1985) have likewise shown that nicotine given intravenously stimulates the 
firing rate of single units in the substantia nigra pars reticulata and that this effect is 
completely antagonized by mecamylamine. These investigators suggested that peripheral 
mechanisms are also involved in this action of nicotine in that the bisquaternary ganglionic 
blocker chlorisondarnine antagonized most of nicotine's effects when given intravenously. 
The effects of nicotine and nicotinic antagonists on the other areas found to contain large 
numbers of 3H-L-nicotine binding sites has not been documented. 
3H-L-Nicotine binding was found to be dense in those areas in which nicotine has been 
shown to possess effects on neurotransmitter release and neuronal firing rate which are 
antagonized by mecamylamine and pempidine. The experiments cited above unfortunately 
do not address the issue of competitive or noncompetitive antagonism of nicotine by these 
compounds. The inability of pempidine to effectively displace 3H-L-nicotine binding to all 
of these areas clearly demonstrates that these compounds do not compete for the agonist 
binding sites that have been elucidated to date. These findings show that the inability to 
detect displacement of agonist binding by the antagonists is not due to the inability to 
measure the binding in areas that are specifically rich in nicotine binding sites by in vitro 
techniques. Therefore, nicotinic antagonists do not compete effectively for 3H-L-nicotine 
in situ binding even in specific brain regions containing a large density of nicotine binding 
sites, suggesting that pempidine is a noncompetitive antagonist of nicotine. 
Evidence for the noncompetitive nature of pempidine's antagonism of nicotine is further 
strengthened by the lack of 3H-pempidine binding under conditions that result in 
high-affinity agonist binding. Since nicotine did not affect the binding of 3H-pempidine to 
brain tissue, it is unlikely that the inability of these compounds to displace agonist binding 
can be explained by an agonist-induced shift of the receptor to an antagonist-insensitive 
state, as suggested by Romano and Goldstein (1980). The inability of 3H-pempidine to 
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bind to brain tissue is surprising due to its  relatively potent antagonistic properties. 
However, it is clear that if a binding site exists for the antagonists, its characteristics are 
distinct from those of the agonist binding sites that have been elucidated to date. The 
results of these binding studies with both nicotine and pempidine suggest that these 
compounds act at mutually exclusive sites. 
The elusive issue that these studies do not address is the functional significance of these 
3H-L-nicotine binding sites and their relevance to nicotine's phannacology. Although it is 
clear that pempidine neither competes for 3H-L-nicotine binding to specific nuclei rich in 
agonist binding sites nor binds to brain tissue itself under conditions maximized for agonist 
binding, one cannot conclude that pempidine is a noncompetitive antagonist of all of 
nicotine's effects based on binding studies alone. Several investigators have argued that 
these high-affinity binding sites have functional significance based on the fact that 
upregulation occurs following chronic treatment (Marks et al. , 1983; Schwartz and Kellar, 
1 983). This may suggest however, that the high-affinity states are associated with 
tolerance and receptor desensitization as opposed to behavioral effects and receptor 
activation. Such a model has been proposed for nicotinic receptors in electric eel 
(Conti-Tranconi et al. ,  1982). 
Other strong evidence in favor of the functional significance of these high-affinity 
binding sites is that the localization patterns for nicotine's metabolic effects and 
high-affinity binding sites are well correlated (London, 1985). However, if the sites that 
lead to receptor desensitization and activation are present on the same macrocolecule, such a 
f"mding would not be unexpected. Nicotine has been shown to cause both activation and 
desensitization of purified, reconstituted nicotinic receptors from electroplaque 
(Conti-Tranconi et aI. ,  1982). These investigators suggest that distinct agonist binding 
sites modulate these effects that are present on the same macromolecule. The fact that 
mecamylamine completely antgonizes nicotine's metabolic effects and yet does not displace 
agonist binding even at micromolar concentrations suggests that these binding sites may not 
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mediate the behavioral and metabolic effects of nicotine. It is interesting that nicotine's 
effects on neurotransmitter release and neuronal excitation cited above occur only at 
micromolar concentrations. This brings the relevance of agonist binding sites of 
nanomolar affinity into question. Of course, it is possible that the preparations used can 
only detect effects that are reasonably large compared to those necessary for nicotine to 
exert behavioral effects in the whole animal. However, nicotine has been shown to 
produce antinociception only at doses that result in micromolar concentrations in plasma 
(Tripathi et al. , 1982). Therefore, central nicotinic antagonists do not compete for 
high-affinity 3H-L-nicotine binding to relevant brain areas, suggesting that either these 
compounds are noncompetitive antagonists, or that these high-affmity agonist binding sites 
do not mediate nicotine's behavioral, biochemical, or electrophysiological effects in brain. 
IV. General Discussion 
The research presented in this thesis was undertaken to address the ambiguity of the 
mechanism of action of nicotinic antagonists in the brain. The assumption of 
noncompetitive antagonism of nicotine by these compounds has been based largely upon 
the fact that they do not displace 3H-nicotine or 3H-acetylcholine binding to brain tissue in 
vitro. Pharmacological studies to corroborate this assumption are lacking, however. The 
study by Stolerrnan et al. (1987) using drug discrimination was difficult to interpret due to 
confounding behavioral effects of nicotine. Although the mechanims of action of these 
compounds has been studied extensively in the periphery, there is some discrepancies 
regarding their competitive or noncompetitive nature at the ganglion as well (van Rossum et 
al. ,  1962). The recent findings that peripheral and central nicotinic cholinergic receptors 
display distinct biochemical characteristics makes extrapolation of these findings to the 
brain even more difficult (Whiting and Lindstrom, 1988). 
Two assays for nicotine's central effects, namely depression of spontaneous activity 
and antinociception, were chosen for the evaluation of pempidine's antagonism of nicotine. 
The range of doses of nicotine that could be studied was greater than for drug 
discrimination due to fewer confounding behavioral effects. Pempidine displayed different 
characteristics with regard to antagonism of these effects of nicotine. The antagonism of 
nicotine-induced hypoactivity displayed the characteristics of competitive antagonism, 
wheras antinociception produced by nicotine was antagonized by pempidine in a 
noncompetitive manner. It is possible that two mechanisms for the antagonists exist, one 
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that is competitive and another being noncompetitive. However, the structure-activity 
relationship of analogs of mecamylamine's antagonism of these effects of nicotine does not 
suggest two distinct mechanisms. The structural requirements for antagonism of nicotine's 
depression of spontaneous activity and production of antinociception were found to be 
identical. If the agonists and antagonists shared common binding sites for modulation of 
motor activity, but not for pain modulation, then the structural requirements for antagonism 
of these effects should be different. The structure-activity relationship that was found for 
the antagonists was different than what has been previously reported for nicotinic agonists 
in the brain (Martin, 1986). 
There are other possible explanations for this discrepancy. Stolennan ( 1 987) has 
postulated that central depression is a nonspecific effect of nicotine, although antagonism of 
this effect by pempidine and mecamylamine suggests that this is a receptor-mediated effect 
of nicotine. Higher doses of niCotine may cause central depression through non-receptor 
mediated mechanisms that are not antagonized by pempidine. Noncompetitive antagonism 
of spare nicotine receptors for depression of spontaneous activity by pempidine is another 
possible explanation for the inability of pempidine to decrease the maximum effect of 
nicotine in this assay. The pattern of shift of nicotine's dose-response curves for these 
central effects, coupled with the structure-activity studies, do not support a competitive 
action of these antagonists. 
These data therefore suggest that mecamylamine and pempidine act noncompetitively in 
the brain. However, the structural requirements for antagonism of these effects were found 
to be quite minimal. It is possible that the structural changes made in the molecule are not 
sufficient to delineate between multiple mechanisms for these compounds. Arguments 
against a competitive mechanism of action for these compounds have been based largely on 
in vitro binding assays in which the antagonists have not been shown to compete 
effectively for agonist binding (Marks et al. ,  1986). However, such assays have limited 
sensitivity for discrete brain regions and destroy the integrity of the tissue by 
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homogenization. Therefore, in situ studies were perfonned to detennine if the lack of 
sensitivity of the agonist binding sites to displacement by the antagonists is due to 
homogenization of the tissue. Autoradiographic localization of 3H-L-nicotine binding and 
its displacement by pempidine was perfonned to test the hypothesis that the antagonists 
may compete for a subset of agonist binding sites that cannot be chartacterized due to the 
lack of sensitivity of in vitro assays. 
The in situ binding and autoradiography studies strongly suggest that neither of these 
issues are responsible for the lack of ability to find displacement of 3H-L-nicotine binding 
to brain tissue by the antagonists. Pempidine did not effectively displace agonist binding to 
any of the areas studied. However, these studies did not address the other explanations 
that have been offered with regard to the antagonist's lack of ability to displace agonist 
binding, namely that the agonists are capable of inducing an agonist-selective state of the 
receptor and thereby preventing antagonist binding (Romano and Goldstein, 1 980). 
Therefore, binding studies with 3H-pempidine were conducted to address these issues and 
to determine if the chartacteristics of agonist and antagonist binding to brain are similar. 
The binding studies with 3H-pempidine in vitro and in situ clearly demonstrate that, if an 
antagonist binding site exists, its characteristics are undoubtedly different from the agonist 
binding sites that have been elucidated to date. The inability of 3H-pempidine to bind to 
brain tissue in a saturable manner under the myriad of conditions studied suggest quite 
strongly that the antagonists do not interact with the agonist binding sites that are labelled 
by these methods. These studies, taken together with the behavioral studies, demonstrate 
that pempidine and mecamylamine are noncompetitve antagonists of nicotine in the brain . 
The noncompetitive nature of these compounds introduces several important questions 
pertaining to nicotine's pharmacology. Since these compounds do not appear to share a 
binding site with acetylcholine, then there may be some other endogenous compound that 
serves as a nicotinic agonist or antagonist centrally. The identification of such a compound 
would greatly enhance the knowledge of nicotine's pharmacology and of the nicotinic 
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cholinergic system. This compound may serve to  modulate cholinergic function in  the 
CNS and therefore have a role in nicotine dependence as well as pathological states 
associated with cholinergic disfunction. Mecamylamine has been shown to increase 
smoking in humans (Stolerman et ai. ,  1973). Comparisons of the levels of a putative 
endogenous nicotinic antagonist in smokers and nonsmokers may yield insights into the 
mechanism by which nicotine reinforces the use of tobacco. Similar studies in animals 
might yield insights into the fundamental reinforcing properties of the nicotinic cholinergic 
system. Loss of cortical nicotinic receptors and basal forebrain cholinergic function has 
been shown to be the most consistent findings associated with Alzheimer's disease 
(Whitehouse and Kellar, 1987). Furthermore, the degree of senile dementia and other 
symptoms of this disorder have been shown to be correlated with the degree of neuronal 
loss (Whitehouse and Kellar, 1987). Similar fmdings have also been reported for dementia 
associated with Parkinson's disease (Whitehouse et al., 1986). It is therefore feasible that 
an endogenous antagonist of the nicotinic cholinergic system may have a role in this 
disorder, as well as senile dementia that is not due to Alzheimer's disease. Nicotine has 
been shown to increase learning and memory in humans and animals (Wesnes and 
Warburton, 1984; Iwamoto et al., 1987). Therefore, the noncompetitive nature of nicotinic 
antagonists in the CNS poses interesting questions pertaining to nicotine's pharmacology. 
The inability of these antagonists to bind to brain tissue is puzzling due to the potency 
and specificity of their action. It is possible that these compounds interact with a 
conformation of the nicotinic receptor that exists only in vivo. These compounds 
antagonize practically all of nicotine's elecrrophysioiogical, biochemical, and behavioral 
effects regardless of the type of tissue and species studied, suggesting that the aspects of 
the nicotinic cholinergic receptor involving the antagonists have been preserved throughout 
the evolution of this system. The study of the relationship between the agonists and 
antagonists would be greatly enhanced if radioligand binding could be studied with 
functional nicotinic receptors. Correlations of the affinity of the receptor for the agonist 
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with receptor desensitization may provide insights into the issue of the functional 
significance of the high-affinity binding sites. Such a preparation may also be necessary 
for the antagonists to bind to their receptor, if such a receptor exists. These studies could 
be performed in vivo in awake animals or possibly ex vivo to superfused brain slices. 
Nicotine has been shown to release dopamine from striatal slices in such a preparation 
(Giorguieff et al., 1975). This effect is antagonized by mecamylamine (Giorguieff et al. ,  
1975) and pempidine (Giorguieff et al. ,  1976). Although this research clearly 
demonstrates that mecamylamine and pempidine do not act at the same binding site as 
nicotinic agonists, the mechanism by which this antagonism occurs is unknown. 
Noncompetitve antagonism could occur if the antagonists bind to an allosteric site on the 
nicotinic receptor-ionophore complex that results in channel blockade or inactivation. 
Alternatively, this binding could result in accelerated dissociation of the agonists from their 
binding site. The most appropriate way to address these issues is by correlating 
electrophysiological, biochemical, or behavioral effects of the agonists and antagonists with 
receptor binding in the same preparation. 
The research presented in this thesis demonstrates that mecamylamine and pempidine 
do not display the characteristics of competitive antagonism of nicotine in the brain. The 
differences in the structural requirements for agonistic and antagonistic potency suggest that 
nicotine and mecamylamine act at different sites in the brain. The binding studies with 
PH]-nicotine and [3H]-pempidine support this conclusion. Therefore, mecamylamine and 
pempidine antagonize nicotine in the brain through a noncompetitive mechanism of action. 
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